EP2649206B1 - Predicting and treating diabetic complications - Google Patents
Predicting and treating diabetic complications Download PDFInfo
- Publication number
- EP2649206B1 EP2649206B1 EP11847055.8A EP11847055A EP2649206B1 EP 2649206 B1 EP2649206 B1 EP 2649206B1 EP 11847055 A EP11847055 A EP 11847055A EP 2649206 B1 EP2649206 B1 EP 2649206B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- subject
- protein
- level
- factors
- rbp3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000002249 Diabetes Complications Diseases 0.000 title 1
- 206010012655 Diabetic complications Diseases 0.000 title 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 232
- 239000002243 precursor Substances 0.000 claims description 74
- 102100038247 Retinol-binding protein 3 Human genes 0.000 claims description 73
- 238000011282 treatment Methods 0.000 claims description 57
- 239000003795 chemical substances by application Substances 0.000 claims description 25
- 108010048996 interstitial retinol-binding protein Proteins 0.000 claims description 23
- 239000003814 drug Substances 0.000 claims description 12
- 229940124597 therapeutic agent Drugs 0.000 claims 10
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 135
- 208000033679 diabetic kidney disease Diseases 0.000 description 135
- 108090000623 proteins and genes Proteins 0.000 description 103
- 235000018102 proteins Nutrition 0.000 description 83
- 102000004169 proteins and genes Human genes 0.000 description 83
- 101000665873 Homo sapiens Retinol-binding protein 3 Proteins 0.000 description 68
- 230000001681 protective effect Effects 0.000 description 65
- 101000904152 Homo sapiens Transcription factor E2F1 Proteins 0.000 description 64
- 201000007917 background diabetic retinopathy Diseases 0.000 description 54
- 238000000034 method Methods 0.000 description 50
- 108010029485 Protein Isoforms Proteins 0.000 description 43
- 102000001708 Protein Isoforms Human genes 0.000 description 43
- 210000004027 cell Anatomy 0.000 description 43
- 239000000523 sample Substances 0.000 description 41
- 206010012601 diabetes mellitus Diseases 0.000 description 39
- 210000002381 plasma Anatomy 0.000 description 33
- 230000000694 effects Effects 0.000 description 28
- 210000001508 eye Anatomy 0.000 description 26
- 239000000203 mixture Substances 0.000 description 25
- 125000003275 alpha amino acid group Chemical group 0.000 description 24
- 239000012634 fragment Substances 0.000 description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 23
- 210000003734 kidney Anatomy 0.000 description 23
- 150000007523 nucleic acids Chemical class 0.000 description 23
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 20
- 201000010099 disease Diseases 0.000 description 20
- 102000039446 nucleic acids Human genes 0.000 description 20
- 108020004707 nucleic acids Proteins 0.000 description 20
- 101000987493 Homo sapiens Phosphatidylethanolamine-binding protein 1 Proteins 0.000 description 19
- 235000001014 amino acid Nutrition 0.000 description 17
- 108090000765 processed proteins & peptides Proteins 0.000 description 17
- 102100028489 Phosphatidylethanolamine-binding protein 1 Human genes 0.000 description 15
- 239000008194 pharmaceutical composition Substances 0.000 description 14
- 210000001525 retina Anatomy 0.000 description 14
- 239000000499 gel Substances 0.000 description 13
- 238000001476 gene delivery Methods 0.000 description 13
- 239000002773 nucleotide Substances 0.000 description 13
- 125000003729 nucleotide group Chemical group 0.000 description 13
- 102100033053 Glutathione peroxidase 3 Human genes 0.000 description 12
- 101000871067 Homo sapiens Glutathione peroxidase 3 Proteins 0.000 description 12
- 150000001413 amino acids Chemical class 0.000 description 12
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 11
- 102100026897 Cystatin-C Human genes 0.000 description 11
- 206010038934 Retinopathy proliferative Diseases 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 11
- 239000000090 biomarker Substances 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 239000003550 marker Substances 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
- 102100035846 Pigment epithelium-derived factor Human genes 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 241001430294 unidentified retrovirus Species 0.000 description 9
- 102100040870 Glycine amidinotransferase, mitochondrial Human genes 0.000 description 8
- 241000700605 Viruses Species 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 239000008103 glucose Substances 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 239000013598 vector Substances 0.000 description 8
- 239000003981 vehicle Substances 0.000 description 8
- 239000013603 viral vector Substances 0.000 description 8
- 108090000102 pigment epithelium-derived factor Proteins 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 230000002207 retinal effect Effects 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- 241000701161 unidentified adenovirus Species 0.000 description 7
- 210000002700 urine Anatomy 0.000 description 7
- 238000001262 western blot Methods 0.000 description 7
- 102100028003 Catenin alpha-1 Human genes 0.000 description 6
- 108010061642 Cystatin C Proteins 0.000 description 6
- 102100026823 Guanosine-3',5'-bis(diphosphate) 3'-pyrophosphohydrolase MESH1 Human genes 0.000 description 6
- 102100033995 Long-chain-fatty-acid-CoA ligase 1 Human genes 0.000 description 6
- 102100028167 NAD(P)H-hydrate epimerase Human genes 0.000 description 6
- 102100025219 Ras-related protein Rab-6A Human genes 0.000 description 6
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 6
- 210000002889 endothelial cell Anatomy 0.000 description 6
- 238000001415 gene therapy Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 102100034482 AP-1 complex subunit beta-1 Human genes 0.000 description 5
- 102100033312 Alpha-2-macroglobulin Human genes 0.000 description 5
- 101000912205 Homo sapiens Cystatin-C Proteins 0.000 description 5
- 101001135402 Homo sapiens Prostaglandin-H2 D-isomerase Proteins 0.000 description 5
- 102100033279 Prostaglandin-H2 D-isomerase Human genes 0.000 description 5
- 102100028644 Tenascin-R Human genes 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 102000049142 human PEBP1 Human genes 0.000 description 5
- 238000004949 mass spectrometry Methods 0.000 description 5
- 230000002062 proliferating effect Effects 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 102100040038 Amyloid beta precursor like protein 2 Human genes 0.000 description 4
- 102000005666 Apolipoprotein A-I Human genes 0.000 description 4
- 108010059886 Apolipoprotein A-I Proteins 0.000 description 4
- 102100037021 Citrate synthase, mitochondrial Human genes 0.000 description 4
- 241000702421 Dependoparvovirus Species 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102100041034 Glucosamine-6-phosphate isomerase 1 Human genes 0.000 description 4
- 102100038055 Glutathione S-transferase theta-1 Human genes 0.000 description 4
- 108010073791 Glycine amidinotransferase Proteins 0.000 description 4
- 102100034629 Hemopexin Human genes 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 101000988834 Homo sapiens Hypoxanthine-guanine phosphoribosyltransferase Proteins 0.000 description 4
- 101000632037 Homo sapiens NAD(P)H-hydrate epimerase Proteins 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 208000009857 Microaneurysm Diseases 0.000 description 4
- 102100023616 Neural cell adhesion molecule L1-like protein Human genes 0.000 description 4
- 208000017442 Retinal disease Diseases 0.000 description 4
- 206010038923 Retinopathy Diseases 0.000 description 4
- 102100030057 Seizure protein 6 homolog Human genes 0.000 description 4
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 230000036470 plasma concentration Effects 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000004393 prognosis Methods 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 238000004885 tandem mass spectrometry Methods 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
- -1 urine Substances 0.000 description 4
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 3
- 101710112984 20 kDa protein Proteins 0.000 description 3
- 102100027824 3'(2'),5'-bisphosphate nucleotidase 1 Human genes 0.000 description 3
- 102100022974 AP-2 complex subunit alpha-2 Human genes 0.000 description 3
- 102100033888 Actin-related protein 2/3 complex subunit 4 Human genes 0.000 description 3
- 102100027241 Adenylyl cyclase-associated protein 1 Human genes 0.000 description 3
- 102100030233 Agmatinase, mitochondrial Human genes 0.000 description 3
- 206010002329 Aneurysm Diseases 0.000 description 3
- 101001099930 Arabidopsis thaliana Ras-related protein RABH1b Proteins 0.000 description 3
- 102100031500 Beta-1,4-glucuronyltransferase 1 Human genes 0.000 description 3
- 102100025991 Betaine-homocysteine S-methyltransferase 1 Human genes 0.000 description 3
- 201000004569 Blindness Diseases 0.000 description 3
- 102100029968 Calreticulin Human genes 0.000 description 3
- 208000002177 Cataract Diseases 0.000 description 3
- 101710106615 Catenin alpha-1 Proteins 0.000 description 3
- 101710195882 Citrate synthase, mitochondrial Proteins 0.000 description 3
- 102100031162 Collagen alpha-1(XVIII) chain Human genes 0.000 description 3
- 102100034583 Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit 1 Human genes 0.000 description 3
- 102100022272 Fructose-bisphosphate aldolase B Human genes 0.000 description 3
- 102100021223 Glucosidase 2 subunit beta Human genes 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101710193792 Guanosine-3',5'-bis(diphosphate) 3'-pyrophosphohydrolase MESH1 Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000935623 Homo sapiens 3'(2'),5'-bisphosphate nucleotidase 1 Proteins 0.000 description 3
- 101000779222 Homo sapiens AP-1 complex subunit beta-1 Proteins 0.000 description 3
- 101000757394 Homo sapiens AP-2 complex subunit alpha-2 Proteins 0.000 description 3
- 101000925566 Homo sapiens Actin-related protein 2/3 complex subunit 4 Proteins 0.000 description 3
- 101000652415 Homo sapiens Agmatinase, mitochondrial Proteins 0.000 description 3
- 101000933413 Homo sapiens Betaine-homocysteine S-methyltransferase 1 Proteins 0.000 description 3
- 101000793651 Homo sapiens Calreticulin Proteins 0.000 description 3
- 101000859063 Homo sapiens Catenin alpha-1 Proteins 0.000 description 3
- 101000940068 Homo sapiens Collagen alpha-1(XVIII) chain Proteins 0.000 description 3
- 101000848781 Homo sapiens Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit 1 Proteins 0.000 description 3
- 101000920078 Homo sapiens Elongation factor 1-alpha 1 Proteins 0.000 description 3
- 101000896557 Homo sapiens Eukaryotic translation initiation factor 3 subunit B Proteins 0.000 description 3
- 101000755933 Homo sapiens Fructose-bisphosphate aldolase B Proteins 0.000 description 3
- 101001040875 Homo sapiens Glucosidase 2 subunit beta Proteins 0.000 description 3
- 101000629379 Homo sapiens Guanosine-3',5'-bis(diphosphate) 3'-pyrophosphohydrolase MESH1 Proteins 0.000 description 3
- 101001083553 Homo sapiens Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial Proteins 0.000 description 3
- 101000840258 Homo sapiens Immunoglobulin J chain Proteins 0.000 description 3
- 101001090172 Homo sapiens Kinectin Proteins 0.000 description 3
- 101000799318 Homo sapiens Long-chain-fatty-acid-CoA ligase 1 Proteins 0.000 description 3
- 101000573300 Homo sapiens NADH dehydrogenase [ubiquinone] iron-sulfur protein 2, mitochondrial Proteins 0.000 description 3
- 101001072202 Homo sapiens Protein disulfide-isomerase Proteins 0.000 description 3
- 101001098802 Homo sapiens Protein disulfide-isomerase A3 Proteins 0.000 description 3
- 101001098824 Homo sapiens Protein disulfide-isomerase A4 Proteins 0.000 description 3
- 101001077400 Homo sapiens Ras-related protein Rab-6A Proteins 0.000 description 3
- 101000658478 Homo sapiens Tubulin monoglycylase TTLL3 Proteins 0.000 description 3
- 102100030358 Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial Human genes 0.000 description 3
- 102100029571 Immunoglobulin J chain Human genes 0.000 description 3
- 102100034751 Kinectin Human genes 0.000 description 3
- 101710159433 Long-chain-fatty-acid-CoA ligase 1 Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 102100033256 Mitochondrial amidoxime reducing component 2 Human genes 0.000 description 3
- 101710159910 Movement protein Proteins 0.000 description 3
- 102100026360 NADH dehydrogenase [ubiquinone] iron-sulfur protein 2, mitochondrial Human genes 0.000 description 3
- 102100036352 Protein disulfide-isomerase Human genes 0.000 description 3
- 102100037097 Protein disulfide-isomerase A3 Human genes 0.000 description 3
- 102100037089 Protein disulfide-isomerase A4 Human genes 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 102100034859 Tubulin monoglycylase TTLL3 Human genes 0.000 description 3
- 101710090398 Viral interleukin-10 homolog Proteins 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 108010005168 alpha 2 subunit adaptor protein complex 2 Proteins 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 210000001742 aqueous humor Anatomy 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 229940120638 avastin Drugs 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 208000017169 kidney disease Diseases 0.000 description 3
- 229940076783 lucentis Drugs 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 238000010232 migration assay Methods 0.000 description 3
- 230000002438 mitochondrial effect Effects 0.000 description 3
- 108010028584 nucleotidase Proteins 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000000575 proteomic method Methods 0.000 description 3
- 230000004286 retinal pathology Effects 0.000 description 3
- 229960003471 retinol Drugs 0.000 description 3
- 235000020944 retinol Nutrition 0.000 description 3
- 239000011607 retinol Substances 0.000 description 3
- 230000001177 retroviral effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 108010020387 tenascin R Proteins 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 230000004393 visual impairment Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 2
- 239000013607 AAV vector Substances 0.000 description 2
- 101710166029 AP-1 complex subunit beta-1 Proteins 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- 102100036774 Afamin Human genes 0.000 description 2
- 102100040055 Amyloid beta precursor like protein 1 Human genes 0.000 description 2
- 101710168921 Amyloid beta precursor like protein 2 Proteins 0.000 description 2
- 102000004881 Angiotensinogen Human genes 0.000 description 2
- 108090001067 Angiotensinogen Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102100036597 Basement membrane-specific heparan sulfate proteoglycan core protein Human genes 0.000 description 2
- 102000000905 Cadherin Human genes 0.000 description 2
- 108050007957 Cadherin Proteins 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 108010075016 Ceruloplasmin Proteins 0.000 description 2
- 102100023321 Ceruloplasmin Human genes 0.000 description 2
- 108010001463 Collagen Type XVIII Proteins 0.000 description 2
- 102000047200 Collagen Type XVIII Human genes 0.000 description 2
- 108010027644 Complement C9 Proteins 0.000 description 2
- 102000008929 Complement component C9 Human genes 0.000 description 2
- 102100035436 Complement factor D Human genes 0.000 description 2
- 241000761389 Copa Species 0.000 description 2
- 102100028007 Cystatin-SA Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 206010012688 Diabetic retinal oedema Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102100021977 Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 Human genes 0.000 description 2
- 108050004000 Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 101000722210 Homo sapiens ATP-dependent DNA helicase DDX11 Proteins 0.000 description 2
- 101000890407 Homo sapiens Amyloid beta precursor like protein 1 Proteins 0.000 description 2
- 101000890401 Homo sapiens Amyloid beta precursor like protein 2 Proteins 0.000 description 2
- 101001000001 Homo sapiens Basement membrane-specific heparan sulfate proteoglycan core protein Proteins 0.000 description 2
- 101000729794 Homo sapiens Beta-1,4-glucuronyltransferase 1 Proteins 0.000 description 2
- 101000722958 Homo sapiens Cystatin-SA Proteins 0.000 description 2
- 101000913082 Homo sapiens IgGFc-binding protein Proteins 0.000 description 2
- 101001054843 Homo sapiens Immunoglobulin lambda variable 1-40 Proteins 0.000 description 2
- 101001043562 Homo sapiens Low-density lipoprotein receptor-related protein 2 Proteins 0.000 description 2
- 101001018274 Homo sapiens Mitochondrial amidoxime reducing component 2 Proteins 0.000 description 2
- 101001112222 Homo sapiens Neural cell adhesion molecule L1-like protein Proteins 0.000 description 2
- 101001073422 Homo sapiens Pigment epithelium-derived factor Proteins 0.000 description 2
- 101000620576 Homo sapiens Ras-related protein Rab-14 Proteins 0.000 description 2
- 101000821521 Homo sapiens Saccharopine dehydrogenase-like oxidoreductase Proteins 0.000 description 2
- 101000864751 Homo sapiens Seizure protein 6 homolog Proteins 0.000 description 2
- 101000626125 Homo sapiens Tetranectin Proteins 0.000 description 2
- 101000652736 Homo sapiens Transgelin Proteins 0.000 description 2
- 102100026103 IgGFc-binding protein Human genes 0.000 description 2
- 102100026911 Immunoglobulin lambda variable 1-40 Human genes 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 238000012313 Kruskal-Wallis test Methods 0.000 description 2
- 102000005482 Lipopolysaccharide Receptors Human genes 0.000 description 2
- 108010031801 Lipopolysaccharide Receptors Proteins 0.000 description 2
- 102100021922 Low-density lipoprotein receptor-related protein 2 Human genes 0.000 description 2
- 206010027525 Microalbuminuria Diseases 0.000 description 2
- 101710191474 NAD(P)H-hydrate epimerase Proteins 0.000 description 2
- 101710163900 Neural cell adhesion molecule L1-like protein Proteins 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 108010039918 Polylysine Proteins 0.000 description 2
- 108010071690 Prealbumin Proteins 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 108010026552 Proteome Proteins 0.000 description 2
- 101710134436 Putative uncharacterized protein Proteins 0.000 description 2
- 102100022288 Ras-related protein Rab-14 Human genes 0.000 description 2
- 208000037111 Retinal Hemorrhage Diseases 0.000 description 2
- 238000010847 SEQUEST Methods 0.000 description 2
- 102100021591 Saccharopine dehydrogenase-like oxidoreductase Human genes 0.000 description 2
- 101710082510 Seizure protein 6 homolog Proteins 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 102100024554 Tetranectin Human genes 0.000 description 2
- 102100031013 Transgelin Human genes 0.000 description 2
- 102000009190 Transthyretin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 2
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 108700005077 Viral Genes Proteins 0.000 description 2
- 206010047513 Vision blurred Diseases 0.000 description 2
- 208000034698 Vitreous haemorrhage Diseases 0.000 description 2
- BOPGDPNILDQYTO-NDOGXIPWSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2r,3r,4r,5r)-5-(3-carbamoyl-4h-pyridin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NDOGXIPWSA-N 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 230000001668 ameliorated effect Effects 0.000 description 2
- 229940093740 amino acid and derivative Drugs 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000001772 anti-angiogenic effect Effects 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 210000002469 basement membrane Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000002902 bimodal effect Effects 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 230000001364 causal effect Effects 0.000 description 2
- 210000003986 cell retinal photoreceptor Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 208000020832 chronic kidney disease Diseases 0.000 description 2
- 239000013256 coordination polymer Substances 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 201000011190 diabetic macular edema Diseases 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000004779 membrane envelope Anatomy 0.000 description 2
- 102000035118 modified proteins Human genes 0.000 description 2
- 108091005573 modified proteins Proteins 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 229920000656 polylysine Polymers 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000012723 sample buffer Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 108091068146 02 family Proteins 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 108010030844 2-methylcitrate synthase Proteins 0.000 description 1
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 1
- 101150037123 APOE gene Proteins 0.000 description 1
- 102100024005 Acid ceramidase Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 102100029470 Apolipoprotein E Human genes 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241001598984 Bromius obscurus Species 0.000 description 1
- 108010075254 C-Peptide Proteins 0.000 description 1
- 102100032378 Carboxypeptidase E Human genes 0.000 description 1
- 108010058255 Carboxypeptidase H Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 108010071536 Citrate (Si)-synthase Proteins 0.000 description 1
- 108010028773 Complement C5 Proteins 0.000 description 1
- 102100031506 Complement C5 Human genes 0.000 description 1
- 108010028771 Complement C6 Proteins 0.000 description 1
- 102100024339 Complement component C6 Human genes 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 102100037985 Dickkopf-related protein 3 Human genes 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 229940124143 Endopeptidase inhibitor Drugs 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 description 1
- 101000975753 Homo sapiens Acid ceramidase Proteins 0.000 description 1
- 101000951342 Homo sapiens Dickkopf-related protein 3 Proteins 0.000 description 1
- 101001039324 Homo sapiens Glucosamine-6-phosphate isomerase 1 Proteins 0.000 description 1
- 101000988802 Homo sapiens Hematopoietic prostaglandin D synthase Proteins 0.000 description 1
- 101000604674 Homo sapiens Immunoglobulin kappa variable 4-1 Proteins 0.000 description 1
- 101000874526 Homo sapiens N-acetyllactosaminide beta-1,3-N-acetylglucosaminyltransferase 2 Proteins 0.000 description 1
- 101001108364 Homo sapiens Neuronal cell adhesion molecule Proteins 0.000 description 1
- 101001124867 Homo sapiens Peroxiredoxin-1 Proteins 0.000 description 1
- 101001072091 Homo sapiens ProSAAS Proteins 0.000 description 1
- 101000948324 Homo sapiens Protein CutA Proteins 0.000 description 1
- 101000891845 Homo sapiens Protein FAM3C Proteins 0.000 description 1
- 101000835541 Homo sapiens Target of Nesh-SH3 Proteins 0.000 description 1
- 101000665937 Homo sapiens Wnt inhibitory factor 1 Proteins 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102100038198 Immunoglobulin kappa variable 4-1 Human genes 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 102000019298 Lipocalin Human genes 0.000 description 1
- 108050006654 Lipocalin Proteins 0.000 description 1
- 208000010415 Low Vision Diseases 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 206010063341 Metamorphopsia Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 101710089664 Mitochondrial amidoxime reducing component 2 Proteins 0.000 description 1
- 101000744522 Mus musculus Ras-related protein Rab-22A Proteins 0.000 description 1
- 108050000637 N-cadherin Proteins 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 102100021852 Neuronal cell adhesion molecule Human genes 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102100040557 Osteopontin Human genes 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102100029139 Peroxiredoxin-1 Human genes 0.000 description 1
- 101710204191 Phosphatidylethanolamine-binding protein 1 Proteins 0.000 description 1
- 102100036366 ProSAAS Human genes 0.000 description 1
- 102000048176 Prostaglandin-D synthases Human genes 0.000 description 1
- 108030003866 Prostaglandin-D synthases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100036046 Protein CutA Human genes 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010038848 Retinal detachment Diseases 0.000 description 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
- 101710137010 Retinol-binding protein 3 Proteins 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 102100026544 Target of Nesh-SH3 Human genes 0.000 description 1
- 102000002689 Toll-like receptor Human genes 0.000 description 1
- 108020000411 Toll-like receptor Proteins 0.000 description 1
- 108091005956 Type II transmembrane proteins Proteins 0.000 description 1
- 208000034699 Vitreous floaters Diseases 0.000 description 1
- 102100038258 Wnt inhibitory factor 1 Human genes 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 230000006229 amino acid addition Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000003181 biological factor Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004155 blood-retinal barrier Anatomy 0.000 description 1
- 230000004378 blood-retinal barrier Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 230000002121 endocytic effect Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 230000004129 fatty acid metabolism Effects 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 210000001650 focal adhesion Anatomy 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000012766 histopathologic analysis Methods 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 150000002432 hydroperoxides Chemical class 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000002743 insertional mutagenesis Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000010189 intracellular transport Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000002647 laser therapy Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000018769 loss of vision Diseases 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000032575 lytic viral release Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000006677 mitochondrial metabolism Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 201000003142 neovascular glaucoma Diseases 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000004072 osteoblast differentiation Effects 0.000 description 1
- 230000033116 oxidation-reduction process Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000003068 pathway analysis Methods 0.000 description 1
- 210000003668 pericyte Anatomy 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000000649 photocoagulation Effects 0.000 description 1
- 210000000608 photoreceptor cell Anatomy 0.000 description 1
- 108091008695 photoreceptors Proteins 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical class CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 description 1
- BHMBVRSPMRCCGG-UHFFFAOYSA-N prostaglandine D2 Natural products CCCCCC(O)C=CC1C(CC=CCCCC(O)=O)C(O)CC1=O BHMBVRSPMRCCGG-UHFFFAOYSA-N 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000004144 purine metabolism Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000004264 retinal detachment Effects 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/16—Ophthalmology
- G01N2800/164—Retinal disorders, e.g. retinopathy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Definitions
- DR diabetic retinopathy
- DN diabetic nephropathy
- DR and DN Common complications of diabetes (e.g., long-term diabetes) include DR and DN. Moreover, the majority of diabetics develop DR and/or DN.
- the present invention is based, at least in part, on the discovery of an association between certain biological factors and the incidence, risk, or development of a microvascular complication, e.g., DR (e.g., PDR) and/or DN. Accordingly, the present disclosure provides that certain of the factors disclosed herein can be used, e.g., as biomarkers to diagnose predict risk of developing a microvascular complication, e.g., DR and/or DN. The present disclosure also provides that certain of the factors disclosed herein can be used in the treatment or therapy of a microvascular complication, e.g., DR and/or DN.
- DR vascular endothelial growth factor
- PDR proliferative DR
- VEGF vascular endothelial growth factor
- AVASTIN proliferative DR
- LUCENTIS vascular endothelial growth factor
- DR is the result of microvascular retinal changes.
- the early stage of DR is referred to as non-proliferative diabetic retinopathy (NPDR), which is a stage during which blood vessels do not proliferate.
- NPDR non-proliferative diabetic retinopathy
- NPDR can be separated out into mild NPDR, moderate NPDR, and severe NPDR.
- PDR proliferative diabetic neuropathy
- PDR proliferative diabetic neuropathy
- Late stages may also involve retinal detachment and/or neovascular glaucoma.
- PDR can further be subdivided into two forms: (i) active PDR, wherein the blood vessels continue to develop and form; and (ii) quiescent PDR, which is described as PDR that is no longer active and is seen, e.g., in subjects having been treated with laser therapy.
- Diabetic retinopathy severity grading is described in the following two references: 1: Grading diabetic retinopathy from stereoscopic color fundus photographs--an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1991 May;98(5 Suppl):786-806 . PubMed PMID: 2062513; and 2: Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1991 May;98(5 Suppl):823-33 . PubMed PMID: 2062515. It is defined as follows:
- DN kidney disease or damage that occurs in diabetics. DN is a major cause of sickness and death in persons with diabetes. It is the leading cause of long-term kidney failure and end-stage kidney disease in the United States, and often leads to the need for dialysis or kidney transplantation.
- DMC diabetic microvascular complication
- DR diabetic retinopathy
- DN diabetic nephropathy
- risk factors specific factors (e.g., proteins) are expressed at higher levels (e.g., at least 1.5 fold higher level) in type 1 diabetic individuals without a diabetic microvascular complication (DMC), such as diabetic retinopathy (DR) and diabetic nephropathy (DN), relative to type 1 diabetic individuals with DR or DN, respectively.
- risk factors e.g., proteins
- Tables 2, 4 and Figure 7 provide examples of factors that are expressed at higher levels in type 1 diabetic individuals without DR relative to those with DR.
- Table 6 provides factors with a statistically significant difference in expression (e.g., at least 1.5 fold) between type 1 diabetic individuals without DR and those with DR (see Examples 1 and 4), wherein individuals without DR have a higher level of the factors. These factors are DR protective factors.
- Table 6 DR protective factors, exemplary accession numbers and fold increase in type 1 diabetes individuals without DR relative to those with DR Name of DR protective factor Accession Nos.
- IPI00748395 10.73 10 HSPG2 Basement membrane-specific heparan sulfate proteoglycan core protein precursor EMBI-EBI accession no. IPI00024284 and IPI00024284.5 9.10 11 APLP1 amyloid precursor-like protein 1 isoform 1 precursor UniProt accession no.IPI00607600 and IPI00607600.3 9.10 12 FCGBP IgGFc-binding protein precursor IPI00242956 and NP_003881.2 7.55 13 APLP2 Isoform 1 of Amyloid-like protein 2 precursor EMBL-EBI accession no. IPI00031030 and IPI00031030.1 6.75 14 TAGLN Transgelin EMBL-EBI accession no.
- IPI00216138 and IPI00216138.6 4.20 15 AGT Angiotensinogen precursor EMBL-EBI accession no. IPI00032220 and IPI00032220.28 3.39 16 C9 Complement component C9 precursor EMBL-EBI IPI00022395 and IPI00022395.1 3.27 17 Autotaxin isoform gamma EMBI-EBL IPI00878576 and UniProt accession no. Q13822.3 2.84 18 RBP3 Interphotoreceptor retinoid-binding protein precursor IPI00022337 and IPI00022337.1 2.71 19 Transthyretin EMBL-EBI accession no. IPI00855916 and UniProt accession no.
- Table 4 lists three factors that are expressed at lower levels in type 1 diabetic individuals without DR relative to those with DR.
- Table 7 provides factors with a statistically significant difference in expression (e.g., at least 1.5 fold) between type 1 diabetic individuals without DR and those with DR (see Examples 1 and 4), wherein individuals without DR have a lower level of the factors. These factors are DR risk factors. A fold decrease of "0" indicates essentially undetectable levels of the factor in a subject without DR (i.e., absence of the risk factor).
- Table 7 DR protective factors, exemplary accession numbers and fold decrease in type 1 diabetes individuals without DR relative to those with DR Name of DR risk factor Accession Nos.
- Tables 3, 5 and Figure 8 provide examples of factors that are expressed at higher levels in type 1 diabetic individuals without DN relative to those with DN.
- Table 8 provides factors with a statistically significant difference in expression (e.g., at least 1.5 fold) between type 1 diabetic individuals without DN and those with DN (see Examples 2 and 5), wherein individuals without DN have a higher level of the factors. These factors are DN protective factors.
- Table 8 DN protective factors, exemplary accession numbers and fold increase in type 1 diabetes individuals without DN relative to those with DN Name of DN protective factor Accession Nos.
- ALDOB Fructose-bisphosphate aldolase B IPI00218407 and UniProt Q8NHT3.51 2.36
- CS Citrate synthase mitochondrial precursor IPI00025366 IPI00025366.4 2.06
- Table 5 The bottom half of Table 5 provides examples of factors that are expressed at lower levels in type 1 diabetic individuals without DN relative to those with DN.
- Table 9 provides factors with a statistically significant difference in expression between type 1 diabetic individuals without DN and those with DN (see Example 5), wherein individuals without DN have a lower level of the factors. These factors are DN risk factors.
- Table 9 DN risk factors, exemplary accession numbers and fold decrease in type 1 diabetes individuals without DN relative to those with DN Name of DN risk factor Accession Nos.
- the second to last column of the Table indicates the fold "decrease" as calculated by using 1 as numerators and using the numbers of the last column as denominators.
- the present disclosure provides, inter alia , methods and compositions for diagnosing and predicting risk of developing diabetic microvascular complications (DMCs), e.g., diabetic retinopathy (DR) and or diabetic nephropathy (DN), in a subject.
- DMCs diabetic microvascular complications
- DR diabetic retinopathy
- DN diabetic nephropathy
- the methods may also be used to determine the effectiveness of a therapy for a DMC or the prognosis of a subject.
- a method may comprise determining the level (e.g., protein or expression level) or activity of one or more protective or risk factors of a DMC, such as the factors described herein.
- the methods include obtaining (or providing) a sample from a subject, e.g., a sample of an eye, such as vitreous, aqueous, or retinal tissue; tears; kidney tissue; plasma; or urine, and evaluating the presence and/or level of one or more biomarker described herein (e.g., in Table 2, 3, 4, 5, 6, 8, 7, 9 or Figure 7 or 8 ) in the sample, and comparing the presence and/or level with one or more reference values, e.g., a control reference value that represents a normal level of the protein, e.g., a level in an unaffected subject, and/or a disease reference that represents a level of the proteins associated with DR or DN, e.g., a level in a subject having DR or DN or an increased (high) likelihood of developing DR or DN.
- the biomarker is a DR protective factor listed in Table 6, a DN protective factor listed in Table 8, a DR risk factor listed in Table 7, or
- Certain methods may comprise providing a sample from a subject (e.g., a subject having diabetes, e.g., type 1 diabetes), such as plasma, a kidney sample or an eye sample, e.g., a vitreous sample; determining the level of at least one protein (factor) listed in Table 2, 3, 4, 5, 6, 8, 7, 9 or Figure 7 or 8 , preferably a factor listed in Table 6, 8, 7, or 9, in the sample; and determining whether the at least one protein is present in the sample at levels at least 50%, 75% (i.e., 1 1 ⁇ 2 fold), 100% (i.e., 2 fold), 2.5 fold, 3 fold, 4 fold, 5 fold, 10 fold, 15 fold or higher or lower than a control value (e.g., reference level), wherein the control value is, e.g., the level of the factor in a subject having type 1 diabetes for at least 10, 15, 20, 25, or more years and who has not developed a microvascular complication, and wherein (i) a level of one or more proteins of Table 6 that is
- Certain methods may comprise providing a sample from a subject (e.g., a subject having diabetes, e.g., type 1 diabetes), such as plasma, a kidney sample or an eye sample, e.g., a vitreous sample; determining the level of at least one protein (factor) listed in Table 2, 3, 4, 5, 6, 8, 7, 9 or Figure 7 or 8 , preferably a factor listed in Table 6, 8, 7 or 9, in the sample; and determining whether the at least one protein is present in the sample at levels essentially identical (e.g., at most 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100% higher or lower than) a control value (e.g., reference level), wherein the control value is, e.g., the level of the protein in a subject who has developed a microvascular complication (such as PDR, e.g., active or quiescent PDR; or NPDR, e.g., mild, moderate or severe NPDR), and wherein (i) a level of one
- the level of a DR protective factor in a subject is compared to both that in a subject who is protected, i.e., has not developed DR after at least 5, 10, 15, 20 or more years of disease, and that in a subject who has developed DR, e.g., severe NPDR or PDR, wherein a level of the DR protective factor in the subject that is significantly closer to that in a subject who is protected than to that in a subject having DR indicates that the subject is likely to be protected from developing DR, whereas a level of the DR protective factor in the subject that is significantly closer to that in a subject who has DR, e.g., severe NPDR or PDR, than to that in a subject that is protected indicates that the subject is likely to develop DR, e.g., severe NPDR or PDR.
- the level of a risk factor in a subject is compared to both that in a subject who is protected, i.e., has not developed DR after at least 5, 10, 15, 20 or more years of disease, and that in a subject who has developed DR, e.g., severe NPDR or PDR, wherein a level of the risk factor in the subject that is significantly closer to that in a subject who is protected than to that in a subject having DR indicates that the subject is likely to be protected from developing DR, whereas a level of the risk factor in the subject that is significantly closer to that in a subject who has DR, e.g., severe NPDR or PDR, than to that in a subject that is protected indicates that the subject is likely to develop DR, e.g., severe NPDR or PDR.
- the level of a DN protective factor in a subject is compared to both that of a subject who is protected, i.e., has not developed DR after at least 5, 10, 15, 20 or more years of disease, and that of a subject who has developed DN, wherein a level of the DN protective factor in the subject that is significantly closer to that in a subject who is protected than to that in a subject having DN indicates that the subject is likely to be protected from developing DN, whereas a level of the DN protective factor in the subject that is significantly closer to that in a subject who has DN, than to that of a subject that is protected indicates that the subject is likely to develop DN.
- the level of a DN risk factor in a subject is compared to both that of a subject who is protected, i.e., has not developed DR after at least 5, 10, 15, 20 or more years of disease, and that of a subject who has developed DN, wherein a level of the DN risk factor in the subject that is significantly closer to that in a subject who is protected than to that in a subject having DN indicates that the subject is likely to be protected from developing DN, whereas a level of the DN risk factor in the subject that is significantly closer to that in a subject who has DN, than to that of a subject that is protected indicates that the subject is likely to develop DN.
- a control or reference value may also be a statistically significant value obtained by, e.g., averaging the level of a particular factor present in more than 5, 10, 15, 20, 30, 40, 50, 100 or more individuals with particular characteristic, e.g., diabetes, but no DR or DN, or only mild forms thereof, such as mild NPDR.
- a control or reference value is generally factor specific, and may be the value of the factor, e.g., a statistically significant value of the factor, in (i) one or more subjects that are protected from a microvascular complication or (ii) one or more subjects that have a microvascular complication.
- protected control value for the value found in protected subjects
- disease control value for the value found in diseases subjects.
- a reference value may depend on the stage of the microvascular complication.
- an "RBP3 control value” or “RBP3 reference value” is a control or reference value of RBP3, e.g., the value of RBP3 in one or more subjects that are protected (e.g., a subject having diabetes for over 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 years and not having developed DR; an "RBP3 protected control value”) or the value of RBP3 in one or more subjects that are not protected and have or are likely to develop DR (an "RBP3 disease control value,” such as "RBP3 severe NPDR control value” or "RBP3 PDR control value”).
- the level of RBP3 is measured in a subject, e.g., a subject with type 1 or 2 diabetes, to determine the likelihood of the subject to develop a DR complication, e.g., severe NPDR and PDR.
- the level of RBP3 may be measured, e.g., in the vitreous, retina, plasma or urine of the subject.
- the level of RBP3 may also be predictive of the effectiveness of a treatment or determining the prognosis of a DR complication.
- a method may comprise obtaining a sample from a subject and determining the level of RBP3 in the sample.
- a lower level e.g., 1.5 or 2 fold lower
- a reference value e.g., the level of RBP3 in type 1 diabetes subjects who have not developed DR after at least 5, 10, 15, 20 or more years of disease is indicative of the likelihood of the subject to have or to develop an advanced stage of NPDR, e.g., severe, NPDR or PDR, or a poor prognostic of the DR.
- a method may also comprise comparing the level of RBP3 in a subject to a reference level that is the level of RBP3 (e.g., in the vitreous, retina, plasma or urine) that is present in a subject having NPDR, e.g., mild, moderate or severe NPDR, or having PDR.
- a subject having NPDR e.g., mild, moderate or severe NPDR, or having PDR.
- a subject that is found to have a similar level of RBP3 protein relative to that in a subject having severe NPDR or PDR is likely to develop a DR complication, e.g., severe NPDR or PDR.
- the level of RBP3 in a subject is compared to both that in a subject who is protected, i.e., has not developed DR after at least 5, 10, 15, 20 or more years of disease, and that in a subject who has developed DR, e.g., severe NPDR or PDR, wherein a level of RBP3 in the subject that is significantly closer to that in a subject who is protected than to that in a subject having DR indicates that the subject is likely to be protected from developing DR, whereas a level of RBP3 in the subject that is significantly closer to that in a subject who has DR, e.g., severe NPDR or PDR, than to that in a subject that is protected indicates that the subject is likely to develop DR, e.g., severe NPDR or PDR.
- the level of PEBP1 is measured in a subject, e.g., a subject with type 1 or 2 diabetes, to determine the likelihood of the subject from developing a kidney complication, e.g., DN.
- the level of PEBP1 may also be predictive of the effectiveness of a treatment or determining the prognosis of a kidney complication.
- a method may comprise obtaining a kidney sample (e.g., sample of glomeruli) from a subject and determining the level of PEBP1 in the sample.
- a method may also comprise comparing the level of PEBP1 in a subject to a reference level that is the level of PEBP1 that is present in a subject having DN.
- a subject that is found to have a similar level of PEBP1 protein relative to that of a subject having DN is likely to develop a kidney complication, e.g., DN.
- the level of PEBP1 in a subject is compared to both that of a subject who is protected, i.e., has not developed DR after at least 5, 10, 15, 20 or more years of disease, and that of a subject who has developed DN, wherein a level of PEBP1 in the subject that is significantly closer to that in a subject who is protected than to that in a subject having DN indicates that the subject is likely to be protected from developing DN, whereas a level of RBP3 in the subject that is significantly closer to that in a subject who has DN, than to that of a subject that is protected indicates that the subject is likely to develop DN.
- an increased level of a protective factor or reduced level of a risk factor is predictive of protection from a particular (or single) microvascular complication, such as DR, e.g., PDR, or DN.
- an increased level of a protective factor or reduced level of a risk factor is predictive of protection from more than one microvascular complication, e.g., both DR and DN.
- an increased level of GPX3, e.g., in plasma indicates a reduced risk of a subject to develop DR or DN.
- a method comprises determining the protein level of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30 or more protective or risk factors of Tables 6, 8, 7 or 9.
- a method comprises determining the protein level of 1-58, 1-50, 1-45, 1-40, 1-35, 1-30, 1-25, 1-20, 1-15, 1-10, 1-5, 1-4, 1-3 or 1-2 protective or risk factors set forth in Tables 6, 8, 7 or 9.
- Preferred combinations of protective factors to be measured for determining the likelihood of a subject to have or to develop DR include RBP3 and or more other factors in Table 6.
- the level of PEDF is also measured, wherein an increased level of PEDF is protective against DR, e.g., PDR.
- the level of PEBP1 and that of at least one other factor, e.g., in Table 8 or 9 is measured.
- the level or concentration of protective or risk factors may be determined in a tissue sample, such as a kidney sample (e.g., renal glomeruli sample), eye vitreous or retina, or bodily fluid sample, e.g., urine, blood, plasma, or intraocular fluid.
- a tissue sample such as a kidney sample (e.g., renal glomeruli sample), eye vitreous or retina, or bodily fluid sample, e.g., urine, blood, plasma, or intraocular fluid.
- Protective or risk factors for DR may be measured in an eye sample, e.g., a sample of the vitreous, retina or intraocular fluid, of a subject.
- Protective or risk factors for DN may be measured in a kidney sample, e.g., a renal glomerulus sample.
- a "level of a factor” refers to the quantity or concentration of the protein or RNA (e.g., RNA) of the factor, and may also refer to the measurement of any other factor that results in the determination of the level of the factor (e.g., the measurement of the level of a metabolite of an enzyme may be a measurement of the level of the enzyme). Similarly, measurements of upstream products may also be measurements of the level of a factor.
- the level or concentration of one or more factor is measured in the blood or plasma of a subject.
- the level of GPX3 may be measured in plasma, wherein an increased (or higher) level of GPX3 in plasma of a first subject relative to that in a second subject indicates that the first subject is less likely than the second subject to develop a kidney problem, such as DN; whereas reduced levels of GPX3 in plasma of a first subject relative to that in a second subject indicates that the first subject is more likely than the second subject to develop a kidney problem, e.g., DN (see Example 3).
- the level of RBP3 may be measured in plasma, wherein an increased (or higher) level of RBP3 in plasma of a first subject relative to that in a second subject indicates that the first subject is less likely than the second subject to develop a kidney problem, such as DN; whereas reduced levels of RBP3 in plasma of a first subject relative to that in a second subject indicates that the first subject is more likely than the second subject to develop a DR, e.g., PDR (see Example 6).
- the plasma level or concentration of both GPX3 and RBP3 is measured in a subject, e.g., to determine the likelihood of a subject to develop DR and/or DN.
- any of the other factors described herein may also be measured in plasma, particularly if the factor is a soluble factor, e.g., a factor that is produced in a secreted form from a cell or a factor, e.g., a membrane bound factor, that is shed by a cell.
- a soluble factor e.g., a factor that is produced in a secreted form from a cell or a factor, e.g., a membrane bound factor, that is shed by a cell.
- a higher level of a protective factor e.g., RBP3, or reduced level of a risk factor can also be used as a measure of the success of a treatment.
- a subject having type 1 diabetes who is responding positively to a diabetic treatment may have a higher level of a protective factor and/or a lower level of a risk factor relative to a subject having type 1 diabetes who is not responding to a treatment or to the value of the factor at the beginning of the treatment of the subject.
- an increase in the level of a protective factor and/or a decrease in the level of a risk factor in a subject with type 1 diabetes who is being treated indicates that the subject responds positively to the treatment.
- the presence and/or level of a protein can be evaluated using methods known in the art, e.g., using quantitative immunoassay methods.
- high throughput methods e.g., protein or gene chips as are known in the art (see, e.g., Ch. 12, Genomics, in Griffiths et al., Eds. Modern genetic Analysis, 1999,W. H.
- a treatment e.g., as known in the art or as described herein, can be administered.
- compositions disclosed herein can include agents that detect or bind (e.g., that detect or bind specifically) to a biomarker described herein (e.g., in Table 2, 3, 4, 5, 6, 8, 7, 9 or Figure 7 or 8 , preferably Table 6, 8, 7 or 9).
- agents can include, but are not limited to, for example, antibodies, antibody fragments, and peptides.
- the compositions can be in the form of a kit.
- kits can include one or more agents that can detect or bind (e.g., that detect or bind specifically) to one or more biomarkers described herein (e.g., one or more of the biomarkers disclosed in Table 2, 3, 4, 5, 6, 8, 7, 9 or Figure 7 or 8 , preferably Table 6, 8, 7 or 9) and instructions for use.
- a method comprises determining the level of a protective or risk factor in a subject.
- the measurement may be performed in the subject, e.g., by imaging, or on a sample obtained from a subject. If the level of the factor is determined in a sample of a subject, a method may comprise first obtaining a sample from a subject, e.g., by using a needle or other apparatus to aspirate a sample. A sample may then be sent to a laboratory for determining the level of the factor, following the doctor's instructions. If the measuring is performed in the subject, the subject may be sent to a particular department in the hospital where they handle such matters, following the doctor's instructions.
- the level of the factor, as determined in the laboratory or hospital is then sent back to the doctor who had ordered the measurement, or entered into a computer or data system that is accessible to the doctor.
- the doctor may then compare the value(s) received to reference values, which may, e.g., be present in a computer.
- reference values may, e.g., be present in a computer.
- the doctor may enter the values into a computer, and the computer performs the comparison with one or more control values.
- the computer may also provide the conclusion regarding the likelihood of development of a microvascular complication by the subject.
- the doctor may then discuss the results with the subject, and choose a path forward, e.g., an appropriate treatment; the decision to re-evaluate the level of one or more factors at a later time; or to evaluate other criteria of the subjects, e.g., the presence or absence of certain symptoms.
- a path forward e.g., an appropriate treatment
- the decision to re-evaluate the level of one or more factors at a later time or to evaluate other criteria of the subjects, e.g., the presence or absence of certain symptoms.
- treatment means any manner in which one or more of the symptoms of DR and/or DN are ameliorated or otherwise beneficially altered.
- amelioration of the symptoms of the disorder refers to any lessening, whether permanent or temporary, lasting or transient that can be attributed to or associated with treatment by the compositions and methods of the present invention.
- treatment can include lessening of any symptom associated with DR, including, but not limited to, blurred or distorted vision or difficulty reading, floaters, reduced vision, vision loss, pain, and/or bleeding in the eye.
- DN treatment can include lessening of any symptom associated with DN, including, but not limited to, changes in appetite, change in sleep, protein in serum, weakness, and/or nausea.
- the present disclosure provides methods for treating a microvascular complication, e.g., DR and/or DN, in a subject (e.g., a subject with diabetes (e.g., type 1 and/or type 2 diabetes) by administering to the subject a therapeutically effective amount of one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more, including all) agents that increase the level or activity of one or more of the DR protective factors disclosed in Table 6 for treating or preventing DR or increase the level or activity of one or more of the DN protective factors disclosed in Table 8 for treating or preventing DN.
- a microvascular complication e.g., DR and/or DN
- a treatment comprises administering to a subject in need thereof a therapeutically effective amount of an agent that reduces the level or activity of a DR or DN risk factor of Table 7 or 9, respectively.
- An agent may increase the level or activity of a protective factor or decrease the level or activity of a risk factor by at least 50%, 100% (1 fold), 1 1 ⁇ 2 fold, 2 fold, 3 fold, 4 fold, 5 fold, 10 fold, 15 fold, 20 fold or more.
- a therapeutic method comprises bringing the level or activity of a protective or risk factor essentially to its level or activity in a subject that is protected from the development of a microvascular complication.
- Essentially within its level refers to within less than 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100% of the control value. How close the level or activity can be brought to a control value depends on the particular factor, in particular on how different the level of the factor is in a protected subject versus a diseased subject.
- An agent that increases the level or activity of a protective factor may be a small molecule, a protein comprising the protective factor or a biologically active variant (e.g., fragment) thereof, or a nucleic acid encoding a protein comprising the protective factor or a biologically active variant (e.g., fragment) thereof.
- An agent that reduces the level or activity of a risk factor may be a small molecule, an RNAi inhibitory molecule (e.g., an siRNA or hsRNA molecule), an antisense molecule, a ribozyme, or an aptamer.
- the present disclosure includes treatments comprising administering one or more proteins, or nucleic acid(s) encoding the one or more proteins, consisting of, consisting essentially of, or comprising the amino acid sequences, or variants thereof, that are associated with any one or more of the accession numbers of the factors disclosed in Table 6 and/or 8.
- useful amino acid sequences can have 50%, 60%, 70%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% sequence identity to any one or more of the accession numbers disclosed in Table 6 and/or 8, provided that they retain the necessary biological activity of the factor for its protective characteristics.
- nucleic acid sequences that encode amino acid sequences consisting of, consisting essentially of, or comprising the amino acid sequences associated with any one or more of the accession numbers disclosed in Table 6 and/or 8 or variants thereof.
- useful nucleic acid sequences can encode an amino acid sequence with 50%, 60%, 70%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% sequence identity to any one or more of the accession numbers disclosed in Table 6 and/or 8.
- the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes).
- the length of a reference sequence aligned for comparison purposes is at least 30%, preferably at least 40%, more preferably at least 50%, even more preferably at least 60%, and even more preferably at least 70%, 80%, 90%, or 100% of the length of the reference sequence.
- the amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared.
- Useful proteins can also comprise amino acid sequences consisting of, consisting essentially of, or comprising the amino acid sequences associated with any one or more of the accession numbers disclosed in Table 6 and/or 8 with one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, or any range between any of the afore listed integers, or more than 100) amino acid additions, deletions or substitutions, e.g., conservative amino acid substitutions, provided that the protein retains the necessary biological activity of the factor for its protective characteristics. Conservative amino acid substitutions are known in the art.
- useful proteins can include modified proteins that possess at least a portion of the activity (e.g., biological activity) of the unmodified proteins.
- modified proteins can retain 50%, 60%, 70%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% of the activity (e.g., biological activity) of the unmodified proteins, e.g., the unmodified version of the amino acid sequences associated with any one or more of the accession numbers disclosed in Table 6 and/or 8.
- useful proteins include proteins that comprise a biologically active fragment of any one or more of the factors disclosed in Table 6 and/or 8.
- treatment of DR or prevention of DR can include administering one or more of the following proteins or biologically active variants thereof or nucleic acid encoding such to a subject in need of such treatment or prevention: B3GNT1 N-acetyllactosaminide beta-1,3-N-acetylglucosaminyltransferase (e.g, IPI00009997 and IPI00009997.1), LRP2 Low-density lipoprotein receptor-related protein 2 precursor (e.g., IPI00024292 and IPI00024292.2), CD 14 Monocyte differentiation antigen CD 14 precursor (e.g., IPI00029260 and IPI00029260.2), TNR Isoform 2 of Tenascin-R precursor (e.g., IPI00554760, IPI00554760.1, IPI00554760.2, and IPI00554760.3), BTD Uncharacterized protein BTD (Fragment) (e.g., IPI00744685
- HSPG2 Basement membrane-specific heparan sulfate proteoglycan core protein precursor e.g., EMBI-EBI accession no. IPI00024284 and IPI00024284.5
- APLP1 amyloid precursor-like protein 1 isoform 1 precursor e.g., UniProt accession no. IPI00607600 and IPI00607600.3
- FCGBP IgGFc-binding protein precursor e.g., IPI00242956 and NP_003881.2
- APLP2 Isoform 1 of Amyloid-like protein 2 precursor e.g., EMBL-EBI accession no.
- IPI00031030 and IPI00031030.1 IPI00031030 and IPI00031030.1
- TAGLN Transgelin e.g., EMBL-EBI accession no. IPI00216138 and IPI00216138.6
- AGT Angiotensinogen precursor e.g., EMBL-EBI accession no. IPI00032220 and IPI00032220.28
- C9 Complement component C9 precursor e.g., EMBL-EBI IPI00022395 and IPI00022395.1
- - Autotaxin isoform gamma e.g., EMBI-EBL IPI00878576 and UniProt accession no.
- RBP3 Interphotoreceptor retinoid-binding protein precursor e.g., IPI00022337 and IPI00022337.1
- - Transthyretin EMBL-EBI accession no. IPI00855916 and UniProt accession no. A6XGL1.1
- CST3;CST2 Cystatin-C precursor e.g., EMBL-EBI accession no. IPI00032293 and IPI00032293.1
- A2M Alpha-2-macroglobulin precursor e.g., EMBL-EBI accession no. IPI00478003 and IPI00478003.1
- CP Ceruloplasmin precursor e.g., EMBL-EBI accession no. IPI00017601 and IPI00017601.1.
- treatment of DN or prevention of DN can include administering one or more of the following proteins or biologically active variants thereof or nucleic acid encoding such to a subject in need of such treatment or prevention: IPI00789618 (e.g., HDDC3 Isoform 1 of HD domain-containing protein 3, IPI00789618.3), IPI00178926 (IGJ immunoglobulin J chain and IPI00178926.3), IPI00816799 (Rheumatoid factor D5 light chain (Fragment) and IPI00816799.1), IPI00410215 (BPNT1 Isoform 2 of 3(2),5-bisphosphate nucleotidase 1 and UniProt 095861.85), IPI00009305 (GNPDA1 Glucosamine-6-phosphate isomerase and UniProt P46926.107), IPI00873466 (HPRT1 Uncharacterized protein HPRT1 and NP_003881.2), IPI00893316 (GSTT1
- IPI00022488.1 IPI00218407 (ALDOB Fructose-bisphosphate aldolase B and UniProt Q8NHT3.51), IPI00305360 (AGMAT Agmatinase, mitochondrial precursor and UniProt Q9BSE5.88), IPI00792191 (GATM Glycine amidinotransferase (L-arginine:glycine amidinotransferase) variant), IPI00219446 (PEBP1 Phosphatidylethanolamine-binding protein 1 and EMBL-EBI accession no. IPI00219446.5), and IPI00025366 (CS Citrate synthase, mitochondrial precursor and IPI00025366.4).
- treatment of DR or prevention of DR can include administering an agent that inhibits or reduces the expression or activity of one or more of: CLEC3B Putative uncharacterized protein DKFZp686H17246 (e.g., EBML-EBI accession no. IPI00792115 and IPI00792115.1), AFM Afamin precursor (e.g., IPI00019943), CFD Complement factor D preproprotein (e.g., IPI00165972), and PTGDS in a subject.
- CLEC3B Putative uncharacterized protein DKFZp686H17246 e.g., EBML-EBI accession no. IPI00792115 and IPI00792115.1
- AFM Afamin precursor e.g., IPI00019943
- CFD Complement factor D preproprotein e.g., IPI00165972
- treatment of DN or prevention of DN can include administering an agent that inhibits or reduces the expression or activity of one or more of: IPI00554811 (TTLL3;ARPC4 Actin-related protein 2/3 complex subunit 4 and IPI00554811.2), IPI00215948 (CTNNA1 Isoform 1 of Catenin alpha-1 and IPI00215948.4), IPI00010796 (P4HB Protein disulfide-isomerase precursor and IPI00010796.1), IPI00646415 (RAB 14 20 kDa protein and EMBL-EBI accession no.
- IPI00554811 TTLL3;ARPC4 Actin-related protein 2/3 complex subunit 4 and IPI00554811.2
- IPI00215948 CTNNA1 Isoform 1 of Catenin alpha-1 and IPI00215948.4
- IPI00010796 P4HB Protein disulfide-isomerase precursor and IPI00010796.1
- IPI00025252 PDIA3 Protein disulfide-isomerase A3 precursor and IPI00025252.1
- IPI00008274 CAP1 Adenylyl cyclase-associated protein 1 and UniProt accession no. Q01518.110
- IPI00783726 KTN1 kinectin 1 isoform b and UniProt accession no. Q17RZ5.32
- IPI00025239 NUFS2 NADH dehydrogenase [ubiquinone] iron-sulfur protein 2, mitochondrial precursor and IPI00025239.2
- IPI00217943 RAB6A Isoform 2 of Ras-related protein Rab-6A and UniProt accession no.
- IPI00016621 API2A2 Adaptor-related protein complex 2, alpha 2 subunit variant (Fragment) and UniProt AP2A2.2
- IPI00025874 RPN1 Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 67 kDa subunit pre and IPI00025874.2
- RBP3, e.g., human RBP3, or a biologically active variant thereof is administered to a subject having or likely to develop DR, e.g., PDR, or to protect the cells of a subject from high glucose exposure.
- RBP3 refers to "retinol binding protein 3, interstitial,” and is also referred to as interphotoreceptor retinoid-binding protein, IRBP, D10S64, D10S65, D10S66, and RBPI.
- IRBP interphotoreceptor retinoid-binding protein
- D10S64, D10S65, D10S66, and RBPI interphotoreceptor retinoid-binding protein
- RBP3 is a large glycoprotein known to bind retinoids and found primarily in the interphotoreceptor matrix of the retina between the retinal pigment epithelium and the photoreceptor cells.
- the amino acid sequence of human RBP3 can be divided into four contiguous homology domains with 33-38% identity.
- the precursor of the human RBP3 protein is 1247 aa long and has the amino acid sequence set forth in GenBank Accession No. NP_002891.
- the nucleotide and amino acid sequences of human RBP3 are set forth as SEQ ID NOs: 1 and 2, respectively, and shown in Figure 9 .
- the signal peptide of human RBP3 corresponds to amino acids 1-17.
- the mature protein consists of amino acids 18-1247.
- the protein comprises four domains referred to as Peptidase_S41_IRBP regions.
- a homozygous missense mutation (pAsp1080Asn) in human RBP3 has been reported to be associated with retinitis pigmentosa (den Hollander et al. Invest. Ophthalmol. Vis. Sci. April 2009 vol. 50 no. 4 1864-187 ), and the authors predict that this residue participates in the retinol binding domain of the human RBP3 protein.
- the nucleotide sequence of a cDNA encoding full length human RBP3 precursor (SEQ ID NO: 1) consists of 4289 nucleotides, wherein nucleotides 115 to 3858 encode SEQ ID NO: 2.
- the signal peptide is encoded by nucleotides 115 to 165, and the mature protein is encoded by nucleotides 166 to 3855 of SEQ ID NO: 1.
- Biologically active variants of the full length human RBP3 protein that may be used in therapeutic methods for treating DR include those comprising an amino acid sequence that comprises fewer amino acids than SEQ ID NO: 2 or the mature form thereof, and contains, e.g., at most 5, 10, 20, 30, 50, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000 or more, fewer amino acids.
- a biologically active fragment of human RBP3 may comprise 1, 2, 3 or all 4 homology domains.
- Other biologically active fragments of human RBP3 include those that retain the ability to bind to retinol or other lipid, e.g., they comprise Asp1080.
- Biologically active variants of human RBP3 also include full length immature and mature forms of human RBP3 or fragments thereof that comprise an amino acid sequence that differs from SEQ ID NO: 2 or fragment thereof in at most 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50 or 100 amino acid deletions, additions or substitutions, such as conservative amino acid substitutions.
- Biologically active variants of a human RBP3 protein may also include variants that are at least 70%, 80%, 85%, 90%, 95%, 97%, 98% or 99% identical to the full length mature or precursor human RBP3 protein or a fragment thereof.
- Biologically active variants of human PEBP1 also include full length immature and mature forms of human PEBP1 or fragments thereof that comprise an amino acid sequence that differs from the naturally occurring sequence (e.g., SEQ ID NO: 4; GenBank Accession No. NP_002558; encoded by a nucleotide sequence having GenBank Accession No. NM_002567 and set forth herein as SEQ ID NO: 3; Figure 17 ) or fragment thereof in at most 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50 or 100 amino acid deletions, additions or substitutions, such as conservative amino acid substitutions.
- Biologically active variants of a human PEBP1 protein may also include variants that are at least 70%, 80%, 85%, 90%, 95%, 97%, 98% or 99% identical to the full length mature or precursor human PEBP1 protein or a fragment thereof.
- the present disclosure also includes fusion proteins comprising any one or more amino acid sequence disclosed in Table 6 and/or 8 in combination with a moiety that increases the stability of the fusion protein in vivo (e.g., polyethelene glycol (PEG)) and/or that increases transport of the fusion protein to the therapeutic target (e.g., the eye and/or the kidney).
- a moiety that increases the stability of the fusion protein in vivo e.g., polyethelene glycol (PEG)
- PEG polyethelene glycol
- protein may be administered systemically or locally.
- a protein for treating or preventing DR e.g., human RBP3 or a biologically active variant thereof, may be administered directly into the eye, e.g., in the vitreous, e.g., by injection.
- a protein may be injected into the eye using the same or a similar methodology as that used for administered LUCENTIS or AVASTIN to the eye of a subject.
- An agent for treating or preventing DR may also be administered to the eye in the form of drops or a periocular injection (peribulbar or subconjunctival).
- a protein for treating DR e.g., human RBP3 or a biologically active variant thereof, may be administered with another agent for treating or preventing DR, such as LUCENTIS or AVASTIN.
- Another agent for treating or preventing DR such as LUCENTIS or AVASTIN.
- Two or more pharmaceutical agents may be administered simultaneously or sequentially. They may be present in one pharmaceutical composition or more than one pharmaceutical composition.
- Systemic administration is also expected to be functional, e.g., for treating DR, as the retinal blood barrier is leaky in diabetic subjects.
- RBP3 as it does not appear to be expressed in any other tissues than the eye, systemic administration is not expected to cause significant toxicity.
- an agent for treating a subject as described herein is an agent that increases the activity of a factor in Table 6 or 8 or reduces the activity of a factor in Table 7 or 9.
- the present disclosure also contemplates the use of gene therapy methods, e.g., to administer a nucleic acid encoding one or more of the factors (e.g., protective factors) or nucleic acids inhibiting the expression or activity of a DR or DN risk factor disclosed herein to a subject.
- a nucleic acid encoding one or more of the factors e.g., protective factors
- nucleic acids encoding a protein disclosed in Table 6 and/or 8, or a variant thereof, or a nucleic acid encoding the protein that increases the expression, level or activity, of one or more of the factors disclosed in Tables 6 and/or 8 can be incorporated into a gene construct to be used as a part of a gene therapy protocol.
- the disclosure includes targeted expression vectors for in vivo transfection and expression of a polynucleotide that encodes a polypeptide disclosed in Table 6 and/or 8, or an active fragment thereof, in particular cell types, for cells of the eye and/or kidney.
- Expression constructs of such components can be administered in any effective carrier, e.g., any formulation or composition capable of effectively delivering the component gene to cells in vivo.
- Approaches include insertion of the gene in viral vectors, including recombinant retroviruses, adenovirus, adeno-associated virus, lentivirus, and herpes simplex virus-1, or recombinant bacterial or eukaryotic plasmids.
- Viral vectors transfect cells directly; plasmid DNA can be delivered naked or with the help of, for example, cationic liposomes (lipofectamine) or derivatized (e.g., antibody conjugated), polylysine conjugates, gramacidin S, artificial viral envelopes or other such intracellular carriers, as well as direct injection of the gene construct or CaPO4 precipitation carried out in vivo.
- lipofectamine lipofectamine
- derivatized e.g., antibody conjugated
- polylysine conjugates e.g., gramacidin S
- artificial viral envelopes e.g., viral envelopes or other such intracellular carriers
- a preferred approach for in vivo introduction of nucleic acid into a cell is by use of a viral vector containing nucleic acid, e.g., a cDNA.
- a viral vector containing nucleic acid e.g., a cDNA.
- Infection of cells with a viral vector has the advantage that a large proportion of the targeted cells can receive the nucleic acid.
- molecules encoded within the viral vector e.g., by a cDNA contained in the viral vector, are expressed efficiently in cells that have taken up viral vector nucleic acid.
- Retrovirus vectors and adeno-associated virus vectors can be used as a recombinant gene delivery system for the transfer of exogenous genes in vivo , particularly into humans. These vectors provide efficient delivery of genes into cells, and the transferred nucleic acids are stably integrated into the chromosomal DNA of the host.
- the development of specialized cell lines (termed "packaging cells") which produce only replication-defective retroviruses has increased the utility of retroviruses for gene therapy, and defective retroviruses are characterized for use in gene transfer for gene therapy purposes (for a review see Miller, Blood 76:271 (1990 )).
- a replication defective retrovirus can be packaged into virions, which can be used to infect a target cell through the use of a helper virus by standard techniques. Protocols for producing recombinant retroviruses and for infecting cells in vitro or in vivo with such viruses can be found in Ausubel, et al., eds., Current Protocols in Molecular Biology. Greene Publishing Associates, (1989 ), Sections 9.10-9.14, and other standard laboratory manuals. Examples of suitable retroviruses include pLJ, pZIP, pWE and pEM which are known to those skilled in the art.
- Retroviruses have been used to introduce a variety of genes into many different cell types, including epithelial cells, in vitro and/or in vivo (see for example Eglitis, et al. (1985) Science 230:1395-1398 ; Danos and Mulligan (1988) Proc. Natl. Acad. Sci. USA 85:6460-6464 ; Wilson et al. (1988) Proc. Natl. Acad. Sci. USA 85:3014-3018 ; Armentano et al. (1990) Proc. Natl. Acad. Sci.
- adenovirus-derived vectors The genome of an adenovirus can be manipulated, such that it encodes and expresses a gene product of interest but is inactivated in terms of its ability to replicate in a normal lytic viral life cycle. See, for example, Berkner et al., BioTechniques 6:616 (1988 ); Rosenfeld et al., Science 252:431-434 (1991 ); and Rosenfeld et al., Cell 68:143-155 (1992 ).
- adenoviral vectors derived from the adenovirus strain Ad type 5 d1324 or other strains of adenovirus are known to those skilled in the art.
- Recombinant adenoviruses can be advantageous in certain circumstances, in that they are not capable of infecting non-dividing cells and can be used to infect a wide variety of cell types, including epithelial cells (Rosenfeld et al., (1992) supra).
- the virus particle is relatively stable and amenable to purification and concentration, and as above, can be modified so as to affect the spectrum of infectivity.
- introduced adenoviral DNA (and foreign DNA contained therein) is not integrated into the genome of a host cell but remains episomal, thereby avoiding potential problems that can occur as a result of insertional mutagenesis in situ, where introduced DNA becomes integrated into the host genome (e.g., retroviral DNA).
- the carrying capacity of the adenoviral genome for foreign DNA is large (up to 8 kilobases) relative to other gene delivery vectors (Berkner et al., supra; Haj-Ahmand and Graham, J. Virol. 57:267 (1986 ).
- Adeno-associated virus is a naturally occurring defective virus that requires another virus, such as an adenovirus or a herpes virus, as a helper virus for efficient replication and a productive life cycle.
- Adeno-associated virus is a naturally occurring defective virus that requires another virus, such as an adenovirus or a herpes virus, as a helper virus for efficient replication and a productive life cycle.
- Adeno-associated virus is also one of the few viruses that may integrate its DNA into non-dividing cells, and exhibits a high frequency of stable integration (see for example Flotte et al., Am. J. Respir. Cell. Mol. Biol. 7:349-356 (1992 ); Samulski et al., J.
- AAV vector such as that described in Tratschin et al., Mol. Cell. Biol. 5:3251-3260 (1985 ) can be used to introduce DNA into cells.
- a variety of nucleic acids have been introduced into different cell types using AAV vectors (see for example Hermonat et al., Proc. Natl. Acad. Sci. USA 81:6466-6470 (1984 ); Tratschin et al., Mol. Cell.
- non-viral methods can also be employed to cause expression of a nucleic acid compound described herein (e.g., a nucleic acid encoding a polypeptide disclosed in Table 6 or 8, or an active fragment thereof, and/or a nucleic acid that increases the expression and/or activity of a polynucleotide that encodes a polypeptide disclosed in Table 6 or 8 or a nucleic acid that inhibits a protein in Table 7 or 9) in the tissue of a subject.
- a nucleic acid compound described herein e.g., a nucleic acid encoding a polypeptide disclosed in Table 6 or 8, or an active fragment thereof, and/or a nucleic acid that increases the expression and/or activity of a polynucleotide that encodes a polypeptide disclosed in Table 6 or 8 or a nucleic acid that inhibits a protein in Table 7 or 9
- non-viral methods of gene transfer rely on the normal mechanisms used by mammalian cells for the uptake and
- non-viral gene delivery systems can rely on endocytic pathways for the uptake of the subject gene by the targeted cell.
- exemplary gene delivery systems of this type include liposomal derived systems, poly-lysine conjugates, and artificial viral envelopes.
- Other embodiments include plasmid injection systems such as are described in Meuli et al., J. Invest. Dermatol. 116(1):131-135 (2001 ); Cohen et al., Gene Ther. 7(22):1896-905 (2000 ); or Tam et al., Gene Ther. 7(21):1867-74 (2000 ).
- an agent e.g., a gene encoding a factor described herein, e.g., a polynucleotide that encodes a polypeptide disclosed in Table 6 or 8, or an active fragment thereof, or an agent that inhibits the expression or activity of a factor in Table 7 or 9, is entrapped in liposomes bearing positive charges on their surface (e.g., lipofectins), which can be tagged with antibodies against cell surface antigens of the target tissue ( Mizuno et al., No Shinkei Geka 20:547-551 (1992 ); PCT publication WO91/06309 ; Japanese patent application 1047381 ; and European patent publication EP-A-43075 ).
- the gene delivery systems for the therapeutic gene can be introduced into a subject by any of a number of methods, each of which is familiar in the art.
- a pharmaceutical preparation of the gene delivery system can be introduced systemically, e.g., by intravenous injection, and specific transduction of the protein in the target cells will occur predominantly from specificity of transfection, provided by the gene delivery vehicle, cell-type or tissue-type expression due to the transcriptional regulatory sequences controlling expression of the receptor gene, or a combination thereof.
- initial delivery of the recombinant gene is more limited, with introduction into the subject being quite localized.
- the gene delivery vehicle can be introduced by catheter (see U.S. Patent 5,328,470 ) or by stereotactic injection (e.g., Chen et al., PNAS USA 91: 3054-3057 (1994 )).
- the pharmaceutical preparation of the gene therapy construct can consist essentially of the gene delivery system in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is embedded.
- the pharmaceutical preparation can comprise one or more cells, which produce the gene delivery system.
- the present disclosure includes the use of agonists of any one or more of the factors disclosed in Tables 6 and/or 8.
- suitable agonists can increase the expression and/or activity of one or more of the factors disclosed in Tables 6 and/or 8, e.g., by about 2-fold, 3-fold, 4-fold, 5-fold, or more.
- the present disclosure includes the use of antagonists of any one or more of the factors disclosed in Tables 7 and/or 9.
- suitable antagonists can decrease the expression and/or activity of one or more of the factors disclosed in Tables 7 and/or 9, e.g., by about 2-fold, 3-fold, 4-fold, 5-fold, or more.
- IPI International Protein Index
- subject is used throughout the specification to describe an animal, human or non-human, to whom treatment according to the methods described herein is provided.
- the methods disclosed herein can include selecting a subject for treatment.
- a subject can be selected if the subject has or is at risk for developing DR and/or DN, e.g., a subject having diabetes, e.g., type 1 or type 2 diabetes, or a subject who is prediabetic, e.g., having metabolic syndrome, insulin resistance, hyperglycemia, hyperlipidemia or a subject who is overweight or obese, e.g., having a BMI ⁇ 25.
- a subject can be selected if the subject has or is at risk for developing type 1 and/or type 2 diabetes.
- a subject can be selected if the subject is taking or will take insulin, e.g., to treat diabetes.
- One or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more, including all) of the agents, such as factors disclosed herein (e.g., disclosed in Tables 6 and/or 8) or agents inhibiting a factor of Table 7 or 9, can be administered alone or as a pharmaceutical composition (disclosed below) using any mode of administration, e.g., including any mode of administration that results in a therapeutically effective level in the eye (for DR) and/or the kidney (for DN).
- a therapeutically effective level is an amount or level that results in one or more of the symptoms of DR and/or DN being ameliorated or otherwise beneficially altered.
- an exemplary route of administration can include local administration into or onto the eye.
- an exemplary route of administration can include local administration to the kidney.
- Other exemplary modes of administration suitable for either DR or DN include, but are not limited to, oral, parenteral, inhalation (e.g., as a spray), topical, rectal, nasal, buccal, vaginal, and/or via an implanted reservoir.
- parenteral as used herein includes subcutaneous, intracutaneous, intravenous, intramuscular, intra ⁇ articular, intraarterial, intrasynovial, intrasternal, intrathecal, intralesional and intracranial injection or infusion techniques.
- the present invention may be administered according to any of the Food and Drug Administration approved methods, for example, as described in CDER Data Standards Manual, version number 004 (which is available at fda.give/cder/dsm/DRG/drg00301.htm).
- the compositions of the invention can be placed in sustained released formulations (e.g., hydrogels) or implantable devices (e.g., implantable pumps).
- One or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more, including all) of the agents, e.g., factors disclosed herein (e.g., disclosed in Tables 6 and 8) or inhibitors of factors in Table 7 or 9, can be formulated in or as pharmaceutical compositions.
- Such pharmaceutical compositions can contain any conventional non-toxic pharmaceutically-acceptable carriers, adjuvants or vehicles.
- the pH of the formulation may be adjusted with pharmaceutically acceptable acids, bases or buffers to enhance the stability of the formulated compound or its delivery form.
- compositions containing one or more factors can be formulated according to the intended method of administration.
- compositions containing one or more factors can be formulated in a conventional manner using one or more physiologically acceptable carriers or excipients.
- the nature of the pharmaceutical compositions for administration is dependent on the mode of administration and can readily be determined by one of ordinary skill in the art.
- methods for making such formulations are well known and can be found in, for example, Remington's Pharmaceutical Sciences, 18th Ed., Gennaro, ed., Mack Publishing Co., Easton, Pa., 1990 .
- the pharmaceutical composition is sterile or sterilizable.
- compositions featured in the invention can contain carriers or excipients, many of which are known to skilled artisans.
- Excipients that can be used include buffers (for example, citrate buffer, phosphate buffer, acetate buffer, and bicarbonate buffer), amino acids, urea, alcohols, ascorbic acid, phospholipids, polypeptides (for example, serum albumin), EDTA, sodium chloride, liposomes, mannitol, sorbitol, water, and glycerol.
- compositions can be presented in unit dosage form, for example, in ampoules or in multi-dose containers, with an added preservative.
- the compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
- the composition may be in powder form for constitution with a suitable vehicle, for example, sterile pyrogen-free water, before use.
- Agents that enhance delivery into a cell can be used as well, e.g., liposomes or micelles.
- compositions can also be formulated as a depot preparation.
- the compositions can be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
- compositions can also take the form of tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (for example, pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (for example, lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (for example, magnesium stearate, talc or silica); disintegrants (for example, potato starch or sodium starch glycolate); or wetting agents (for example, sodium lauryl sulphate).
- binding agents for example, pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose
- fillers for example, lactose, microcrystalline cellulose or calcium hydrogen phosphate
- lubricants for example, magnesium stearate, talc or silica
- disintegrants for example, potato starch or sodium starch glycolate
- wetting agents for example, sodium lauryl sulphate
- Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use.
- Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (for example, sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (for example, lecithin or acacia); non-aqueous vehicles (for example, almond oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (for example, methyl or propyl-p-hydroxybenzoates or sorbic acid).
- the preparations may also contain buffer salts, flavoring, coloring and sweetening agents as appropriate.
- Preparations for oral administration may be suitably formulated to give controlled release of the active compound.
- Toxicity and therapeutic efficacy of the compounds and pharmaceutical compositions described herein can be determined by standard pharmaceutical procedures, using either cells in culture or experimental animals to determine the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population).
- the dose ratio between toxic and therapeutic effects is the therapeutic index and can be expressed as the ratio LD50/ED50.
- Polypeptides or other compounds that exhibit large therapeutic indices are preferred.
- the dosage of such compounds lies preferably within a range of circulating concentrations that include the ED50 with little or no toxicity.
- the dosage may vary within this range depending upon the dosage form employed and the route of administration utilized.
- the therapeutically effective dose can be estimated initially from cell culture assays.
- a dose can be formulated in animal models to achieve a circulating plasma concentration range that includes the IC50 (that is, the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans.
- the formulations and routes of administration can be tailored to the disease or disorder being treated, and for the specific human being treated.
- a subject can receive a dose of the agent once or twice or more daily for one week, one month, six months, one year, or more.
- the treatment can continue indefinitely, such as throughout the lifetime of the human.
- Treatment can be administered at regular or irregular intervals (once every other day or twice per week), and the dosage and timing of the administration can be adjusted throughout the course of the treatment.
- the dosage can remain constant over the course of the treatment regimen, or it can be decreased or increased over the course of the treatment.
- the dosage facilitates an intended purpose for both prophylaxis and treatment without undesirable side effects, such as toxicity, irritation or allergic response.
- side effects such as toxicity, irritation or allergic response.
- human doses can readily be extrapolated from animal studies ( Katocs et al., Chapter 27 In: Remington's Pharmaceutical Sciences, 18th Ed., Gennaro, ed., Mack Publishing Co., Easton, Pa., 1990 ).
- the dosage required to provide an effective amount of a formulation will vary depending on several factors, including the age, health, physical condition, weight, type and extent of the disease or disorder of the recipient, frequency of treatment, the nature of concurrent therapy, if required, and the nature and scope of the desired effect(s) ( Nies et al., Chapter 3, In: Goodman & Gilman's "The Pharmacological Basis of Therapeutics", 9th Ed., Hardman et al., eds., McGraw-Hill, New York, N.Y., 1996 ).
- the methods can also include monitoring or evaluating the subject during and after treatment to determine the efficacy of the treatment, and, if necessary, adjusting treatment (e.g., by altering the composition, by increasing the dose of a single administration of the composition, by increasing the number of doses of the composition administered per day, and/or by increasing the number of days the composition is administered) to improve efficacy.
- Monitoring or evaluating the subject can include identifying a suitable marker of disease prior to commencing treatment and optionally recording the marker, and comparing the identified or recorded marker to the same marker during and/or after treatment.
- Suitable markers can include one or more symptoms of the subject's disease. Suitable markers also include one or more of the factors described in Tables 6, 8, 7 and 9.
- Adjustment of treatment would be recommended where the marker is a symptom of disease and comparison of the marker during or after treatment with the marker prior to treatment revealed either no change in the marker or an increase in the marker. Conversely, adjustment of treatment may not be required using the same markers where an increase in the marker is observed.
- Retinal pathology was documented by dilated fundus examination and fundus photography.
- the degree of renal disease was assessed through measurements of albumin, creatinine, cystatin C and estimated glomerular filtration rate (eGFR).
- eGFR estimated glomerular filtration rate
- a bimodal distribution of DR was observed with 50% of the Medalists having none to moderate nonproliferative DR and 50% having quiescent PDR ( Fig. 1 and Table 1).
- standard risk factors including duration of diabetes and HbAlC levels, were not associated with severity.
- samples were taken from eight eyes: three with no to moderate NPDR, four with PDR, and one ungradeable (due to scatter laser performed for nondiabetic pathology) as determined by grading of fundus photographs. Retinal pathology was assessed using standard methods.
- proteomic analysis retinal and vitreous specimens were isolated and isolated using mass spectrometry methods as previously described ( Gao et al., J Proteome Res. 2008;7:2516-25 ; Gao et al., Nat Med. 2007;13:181-8 ). Initial analysis of these eight eyes by mass spectrometry identified over 450 proteins.
- APOA1BP Isoform 2 of Apolipoprotein A-1-binding protein precursor interacts with apolipoprotein A-I (apoA-I), the major apolipoprotein of high-density lipoproteins (HDLs) Oxidation reduction / Oxidative Stree Isoform 1 of MOSC domain-containing protein 2, mitochondrial MOSC2 precursor (mt) HPX Hemopexin precursor glycoprotein, binds heme GPX3 Glutathione peroxidase 3 precursor detoxification of hydrogen peroxide GSTT1 Glutathione S-transferase theta 1 PRDX1 peroxiredoxin 1 antioxidant enzymes, reduce hydrogen peroxide and alkyl hydroperoxides Isoform 2 of Hydroxyacyl-coenzyme A dehydrogenase, HADH mitochondrial precursor (mt) also fatty acid metabolism SCCPDH saccharopine dehydrogenase
- Validation of the proteins identified through comparison of those with and without DN will be done using samples of urine, plasma and serum from the Joslin Natural History of Microalbuminuria Studies.
- the validation study is a case-control testing the hypothesis of a significantly lower level of the factor of interest being present in fast progressors, defined as those who have had a greater than 7% eGFR loss of per year over a 10 year period within 15 year duration compared to those with chronic kidney disease classifications 1, 2, or 3.
- Example 3 Plasma levels of DN protective factor GPX3 correlate positively with the GFR
- Candidates identified by our proteomic analysis of the vitreous and kidney are measured in the plasma of normal and type 1 diabetic patients to validate the relationship with protection against DR/DN, and to examine whether there is a temporal relationship with progression of DR/DN.
- GPX3 which was identified as a biomarker in both the vitreous and kidney, a secreted enzyme and is involved in neutralizing hydroxides and preventing lipid peroxidation, was measured plasma GPX3 levels by ELISA method in 40 Medalists and a positive correlation was observed between the level of GPX3 and estimated GFR calculated by cystatin C ( Fig. 3 ).
- PEDF an anti-angiogenic protein representing a major pathway of protective factors identified in the vitreous proteomic study (Table 2), has been assayed in plasma. Levels of PEDF in plasma among those with PDR have been found at 5.3 ⁇ 5.1 ng/mL and among those without at 7.7 ⁇ 6.1 ng/mL ( Matsuyama et al., Mol Vis. 2008 May 28;14:992-6 ). A sample size of 100 cases and 100 controls yields a power of 83% with p ⁇ 0.05).
- FIG.4 The prevalence of DR in the Medalists evaluated is shown in FIG.4 .
- Candidate factors that protect against DR were identified by comparing the levels or expression of factors in individuals with DR and those without DR. Factors with a statistically significant difference in expression between the individuals with DR and those without DR were selected. A total of 700 candidate factors were selected. Further statistical analysis was then applied to select protective factors from the candidate factors. After applying kruskal-wallis statistical analysis, a total of 22 protective factors (the first 22 factors in the Table, i.e., those above the black line) and 3 risk factors (the last three lines in the Table, i.e., those under the black line) were identified, as shown in Table 4 and FIG. 7.
- the analysis was performed essentially as follows. The protein analysis was done using a label-free quantitative analysis of 1D PAGE-LC/MS/MS-based proteomics. Soluble proteins from vitreous tissues of 50-Year Medalists were loaded onto 10% acrylamide protein gels for separations in 1-D gel electrophoresis. We loaded 50uL (micro liter) of vitreous fluid with sample buffer in each sample lane on the gel. Then the gel was stained with Coomassie Blue. Each lane of gel was then cut into 40 slices. The 40 slices were digested in separate tubes by trypsin. These digested protein gel slices were then loaded into an LC machine for the later MS/MS analysis.
- MS manager software previously developed by Benbo Gao ( Gao B et al. Mol Cell Proteomics 2008;7:2399-2409 ).
- MS manager is designed based on the PHP-MySQL-Apache platform. It compiles the search results from SEQUEST and X! Tandem of MS/MS data, and then parses these results into the MySQL database. After applying the algorithm for filtering proteins and combining the IPI identifier, a final report of identified proteins is generated in a table with peptide hit numbers. The results are shown in Table 4 below.
- the first column in Table 4 shows the names of DR protective factors.
- the second column shows the International Protein Index numbers (IPI numbers) of the protective factor proteins. These accession numbers were retrieved from mass spectrometry analysis result, mapped to EMBI-EBI IPI database.
- Columns 3-7 and columns 9-15 show the peptide hits of each factor (reflecting the expression level) from each vitreous sample. Columns 3-7 are hits in samples from subjects having no-mild NPDR, and columns 9-15 are hits from subjects having PDR.
- the first line of the Table refers to the grade of the DR from which each of the samples were obtained (e.g., "2,” “3,” and "0,” refer to NPDR grades 2, 3 and 0, respectively).
- the line listing refers to the name of the samples.
- Column 8 is the average number of hits in no-mild NPDR samples, compiled from columns 3-7 for each factor.
- Column 16 is the average number of hits in PDR samples, complied from columns 9-15.
- Column 17 shows the fold difference between the average number of hits in the no-mild NPDR samples (column 8) to the average number of hits in the PDR samples (column 16) for each factor.
- the fold increase column shows that the factors are expressed at higher levels in type 1 diabetic individuals without DR compared to those with DR.
- Example 5 Identification of factors that protect against DN or increase the risk of DN
- FIG. 5 Complications observed in Medalists are shown in FIG. 5 and a summary of clinical characteristics in Medalists is shown in FIG. 6 .
- Candidate factors that protect against DN were identified by comparing the levels or expression of factors in individuals with DN and those without DN. Factors with a statistically significant difference in expression between the individuals with DN and those without DN were selected. A total of 1709 candidate factors were selected. Further statistical analysis was then applied to select protective factors from the candidate factors.
- FIG. 8 only lists the protective factors.
- the analysis was performed essentially as follows. The protein analysis was done using a label-free quantitative analysis of 1D PAGE-LC/MS/MS-based proteomics. Soluble proteins from vitreous tissues of 50-Year Medalists were loaded onto 10% acrylamide protein gels for separations in 1-D gel electrophoresis. We loaded 200ug (micro gram) of protein-prep (isolated by sieving, buffering, centrifuging, etc. several steps.) with sample buffer in each sample lane on the gel. Then the gel was stained with Coomassie Blue. Each lane of gel was then cut into 40 slices. The 40 slices were digested in separate tubes by trypsin. These digested protein gel slices were then loaded into an LC machine for the later MS/MS analysis.
- MS manager software previously developed by Benbo Gao ( Gao B et al. Mol Cell Proteomics 2008;7:2399-2409 ).
- MS manager is designed based on the PHP-MySQL-Apache platform. It compiles the search results from SEQUEST and X! Tandem of MS/MS data, and then parses these results into the MySQL database. After applying the algorithm for filtering proteins and combining the IPI identifier, a final report of identified proteins is generated in a table with peptide hit numbers. The results are shown in Table 5 below.
- the first column in table 5 shows the International Protein Index numbers (IPI numbers) of the protective factor proteins. These accession numbers were retrieved from mass spectrometry analysis result, mapped to EMBI-EBI IPI database.
- the second column shows names of DN protective factors. Columns 3-5 and columns 7-15 show the peptide hits of each factor (reflecting the expression level) from each kidney sample. Columns 3-5 are hits in samples from subjects with no DN, and columns 7-15 are hits in samples from subjects with DN.
- the first line (listing, e.g., "G7") refers to the names of each sample.
- Column 6 (“Clean Mea”) shows the average number of hits in the non-DN samples, compiled from columns 3-5 for each factor.
- Column 16 is the average number of hits in the DN samples, compiled from columns 9-15.
- Column 17 shows the fold difference between the average number of hits in the no-DN samples (column 6) to the average number of hits in the DN samples (column 16) for each factor.
- the fold column shows that the protective factors (factors 1-15, i.e., those above the line) are expressed at higher levels in type 1 diabetic individuals without DN compared to those with DR. It also shows that the risk factors (factors 16-32, i.e., those below the line) are expressed at lower levels in type 1 diabetic individuals without DN relative to those with DN.
- Example 6 RBP3 protein levels are higher in vitreous of Medalists without PDR than in vitreous from Medalists with PDR
- CST3 is universally expressed. We confirmed that CST3 is detected in mouse retina protein extracts by Western blot (data not shown). RBP3 is secreted by the retinal photoreceptor cells (RPE), and thus, it could play a role in retinal endothelial cells and pericytes even when those cells do not express RBP3.
- RPE retinal photoreceptor cells
- RBP3 was also quantified in the vitreous of Medalists with no-mild NPDR, active PDR or quiescent PDR by proteomics analysis. No to mild NPDR is as described above. "Quiescent PDR" corresponds to ETDRS severity level > 60, characterized by the presence of neovascularization, fibrous proliferation, or panretinal laser photocoagulation scars.
- the level of RBP3 was also determined in the vitreous of Medalists with no to mild NPDR and compared to that in Medalists with PDR using proteomics analysis. The results, which are shown in Figure 13 , indicate that the level of RBP3 is higher in Medalists with no to mild NPDR relative to that in Medalists with PDR.
- Example 7 RBP3 protein levels are higher in the retina of Medalists with mild NPDR relative to that in Medalists with PDR
- the level of RBP3 was also determined in the retina of Medalists with mild NPDR and Medalists with PDR.
- the assay was conducted as follows: 10 ug of protein were loaded onto a 4-20% gel (Biorad) and transferred to a PVDF membrane (Immobilon-P) and immunoblotted as described above.
- Example 8 RBP3 is expressed in human plasma
- Human plasma was obtained from control subjects from the Medalist study at the Joslin Diabetes Center. A blood sample was extracted by venipuncture using standard CLIA protocol after patient consent was obtained using a 10mL EDTA tube by a trained phlebotomist. This was then centrifuged at 4 degrees centigrade for 10 mins at 4000 rpm. After this process the supernatant (plasma) was aliquotted off into 100 mL samples and stored at -80 centigrade. The human plasma was serum albumin and IgG depleted using Pierce kit (89875) following the manufacturers instructions. Equal volumes (20ul) were loaded on a gel and immunoblotted as described above.
- Human RBP3 was prepared as follows: hRBP3 ORF containing plasmid was purchased from Origene (RC08063), transfected into HEK 293 cells using Fugene HD (Promega), the cells lysed and RBP3 was bound to M2 resin (Sigma, Aldrich) and eluted using 1XFlag peptide (Sigma) following the manufacturer's instructions. The purified peptide was confirmed by immunoblotting against the DDK tag, and a 137 kDa band was confirmed.
- BREC bovine retinal endothelial cells
- 3 x 10 4 per well were plated in a 24 well plate.
- the width of this gap was measured at 0 and 4 hours in the corresponding conditions, two pictures of each gap were taken at each time point and the average was used.
- Four wells were plated for each condition. Statistics were done with excel (student ttest).
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Marine Sciences & Fisheries (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Description
- Described herein are compositions and methods for diagnosing or predicting risk of diabetic retinopathy (DR) and/or diabetic nephropathy (DN), and to compositions and methods for treating DR and/or DN.
- Common complications of diabetes (e.g., long-term diabetes) include DR and DN. Moreover, the majority of diabetics develop DR and/or DN.
- The present invention is based, at least in part, on the discovery of an association between certain biological factors and the incidence, risk, or development of a microvascular complication, e.g., DR (e.g., PDR) and/or DN. Accordingly, the present disclosure provides that certain of the factors disclosed herein can be used, e.g., as biomarkers to diagnose predict risk of developing a microvascular complication, e.g., DR and/or DN. The present disclosure also provides that certain of the factors disclosed herein can be used in the treatment or therapy of a microvascular complication, e.g., DR and/or DN.
- Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Methods and materials are described herein for use in the present disclosure; other, suitable methods and materials known in the art can also be used. The materials, methods, and examples are illustrative only and not intended to be limiting. The invention is defined by claims 1-6.
-
-
FIG. 1 is a bar graph showing the bimodal distribution of diabetic retinopathy in the Medalist subject population. -
FIG. 2 is a line graph showing the rate of DR worsening in eyes with and without PDR at the final visit. -
FIG. 3 is a scatter plot showing the correlation of plasma GPX3 Level to estimated GFR in a subset of 50 year medalist subjects. GFR was estimated using equation from Stevens et al, Am J Kidney Dis 2008; 51: 395-40. -
FIG. 4 is a bar graph showing the prevalence of DR status (no DR or mild DR, moderate to severe DR, and proliferative DR ((PDR) advanced disease)) among the subjects described in Examples 4-. -
FIG. 5 is a chart showing microvascular and macrovascular complications in the subjects disclosed in Examples 4-5. -
FIG. 6 is a Table summarizing the clinical characteristics of the subjects disclosed in Examples 4-5. -
FIG. 7 is a Table showing factors identified as being protective against PDR. (n= 5 for no or mild to moderate DR. n=7 for PDR. Data was analyzed using the Kruskal Wallis test.) -
FIG. 8 is a Table showing factors identified as being protective against DN. (n=9 for ACR less than 30 and with a histology class of 1. N= 3 for ACR of greater than 30 and with a histology class greater than 1. Data was analyzed using the Kruskal Wallis test.) -
FIG. 9 shows the amino acid sequence (SEQ ID NO: 2) of full length precursor of human RBP3 (SEQ ID NO: 2). -
FIG. 10 shows the nucleotide sequence (SEQ ID NO: 1) of a cDNA encoding the full length precursor of human RBP3 (SEQ ID NO: 2). -
FIG. 11 shows histograms with the values of RBP3, PTGDS and Cystatin C protein levels in vitreous of Medalists without PDR versus in vitreous from Medalists with PDR, as measured via Western blots. "M" refers to Mild-NPDR and "P" refers to PDR. -
FIG. 12 is a histogram with the values of RBP3 protein levels in vitreous of Medalists without PDR versus in vitreous from Medalists with active PDR or quiescent PDR, as measured via Western blots. -
FIG. 13 represents a Western blot (A) and a diagram (B) showing the levels of RBP3 in vitreous of Medalists with no to mild NPDR ("N") and Medalists with PDR ("PDR"). -
FIG. 14 represents a Western blot (A) and a diagram (B) showing the levels of RBP3 in retina of Medalists with mild NPDR ("N") and Medalists with PDR ("P"). -
FIG. 15 is a Western blot showing the presence of RBP3 in human plasma. -
FIG. 16 is a diagram showing the number of endothelial cells that have migrated in the migration assay, following exposure to low or high glucose concentrations and no treatment, treatment with vehicle alone and treatment with RBP3. -
FIG 17 shows the nucleotide and amino acid sequence of human PEBP1 (SEQ ID NOs: 3 and 4, respectively). - DR is damage that occurs to the retina of the eye in diabetics. Symptoms of DR range from blurred vision to loss of vision. Moreover, DR is a major cause of vision loss in developed countries. Understanding the causal role of vascular endothelial growth factor (VEGF) in the development of the proliferative DR (PDR) and vascular permeability has identified inhibitors of VEGF (e.g., AVASTIN and LUCENTIS) as effective treatments for diabetic neovascularization and macular edema. However, mechanisms by which hyperglycemia propagates the progression of DR are still not fully established. The only proven way to help prevent the initiation and progression of DR is good glycemic control. Several reasons may be responsible for the difficulty in identifying causal factors and effective treatments for the early stages of DR. These include challenges in obtaining retinal tissues in various stages of DR, lack of validated biomarkers and the absence of a salient rodent model. Recent therapeutic advances using inhibitors of VEGF for diabetic macular edema and neovascular lesions of DR are substantial. However, there remains a critical need to evaluate retinal tissue at all stages of DR to identify potential therapeutic targets and to validate potential markers of incidence and progression of DR in diabetic individuals.
- DR is the result of microvascular retinal changes. The early stage of DR is referred to as non-proliferative diabetic retinopathy (NPDR), which is a stage during which blood vessels do not proliferate. NPDR can be separated out into mild NPDR, moderate NPDR, and severe NPDR. As DR progresses, blood vessels start to proliferate (i.e. grow) and new blood vessels form. This stage is referred to as proliferative diabetic neuropathy (PDR). These new blood vessels can bleed, cloud vision, and destroy the retina. Late stages may also involve retinal detachment and/or neovascular glaucoma. PDR can further be subdivided into two forms: (i) active PDR, wherein the blood vessels continue to develop and form; and (ii) quiescent PDR, which is described as PDR that is no longer active and is seen, e.g., in subjects having been treated with laser therapy.
- Diabetic retinopathy severity grading is described in the following two references: 1: Grading diabetic retinopathy from stereoscopic color fundus photographs--an extension of the modified Airlie House classification. ETDRS
report number 10. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1991 May;98(5 Suppl):786-806. PubMed PMID: 2062513; and 2: Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1991 May;98(5 Suppl):823-33. PubMed PMID: 2062515. It is defined as follows: - 1) Mild nonproliferative retinopathy (NPDR); At least one microaneurysm, and definition not met for moderate nonproliferative retinopathy, severe nonproliferative retinopathy, early proliferative retinopathy, or high-risk proliferative retinopathy (see below). ETDRS levels below 35. Level between 10 and 20 is very mild NPDR;
- 2) Moderate NPDR: Hemorrhages and/or microaneurysms ≥ standard photograph 2A*; and/or soft exudates, venous beading, or intraretinal microvascular abnormalities definitely present; and definition not met for severe nonproliferative retinopathy, early proliferative retinopathy, or high-risk proliferative retinopathy (see below). ETDRS levels 35, 43: moderate NPDR less than 4:2:1;
- 3) Severe NPDR: Soft exudates, venous beading, and intraretinal microvascular abnormalities all definitely present in at least two of fields four through seven; or two of the preceding three lesions present in at least two of fields four through seven and hemorrhages and microaneurysms present in these four fields, equaling or exceeding standard photo 2A in at least one of them; or intraretinal microvascular abnormalities present in each of fields four through seven and equaling or exceeding standard photograph 8A in at least two of them; and definition not met for early proliferative retinopathy or high-risk proliferative retinopathy (see below). ETDRS levels 53A-E: severe to very severe NPDR, 4:2:1 rule;
- 4) Early proliferative retinopathy (i.e., proliferative retinopathy without Diabetic Retinopathy Study high-risk characteristics): New vessels; and definition not met for high-risk proliferative retinopathy (see below); and
- 5) High-risk proliferative retinopathy (proliferative retinopathy with Diabetic Retinopathy Study high-risk characteristics): New vessels on or within one disc diameter of the optic disc (NVD) ≥ standard photograph 10A* (about one-quarter to one-third disc area), with or without vitreous or preretinal hemorrhage; or vitreous and/or preretinal hemorrhage accompanied by new vessels, either NVD < standard photograph 10A or new vessels elsewhere (NVE) ≥ one-quarter disc area.
ETDRS levels - * Early Treatment Diabetic Retinopathy Study Research Group. Grading diabetic retinopathy from stereoscopic color fundus photographs--an extension of the modified Airlie House classification. . Adapted from the Early Treatment Diabetic Retinopathy Study Research Group. Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics. .
- DN is kidney disease or damage that occurs in diabetics. DN is a major cause of sickness and death in persons with diabetes. It is the leading cause of long-term kidney failure and end-stage kidney disease in the United States, and often leads to the need for dialysis or kidney transplantation.
- As further described in the Examples, it has been shown herein that specific factors (e.g., proteins) are expressed at higher levels (e.g., at least 1.5 fold higher level) in
type 1 diabetic individuals without a diabetic microvascular complication (DMC), such as diabetic retinopathy (DR) and diabetic nephropathy (DN), relative to type 1 diabetic individuals with DR or DN, respectively. Such factors are referred to as "protective factors." It has also been shown herein that specific factors (e.g., proteins) are expressed at lower levels intype 1 diabetic individuals without DN, relative to type 1 diabetic individuals with DN. Such factors are referred to herein as "risk factors." - Tables 2, 4 and
Figure 7 provide examples of factors that are expressed at higher levels intype 1 diabetic individuals without DR relative to those with DR. Table 6 provides factors with a statistically significant difference in expression (e.g., at least 1.5 fold) betweentype 1 diabetic individuals without DR and those with DR (see Examples 1 and 4), wherein individuals without DR have a higher level of the factors. These factors are DR protective factors.Table 6: DR protective factors, exemplary accession numbers and fold increase in type 1 diabetes individuals without DR relative to those with DRName of DR protective factor Accession Nos. Fold increase 1 B3GNT1 N-acetyllactosaminide beta-1,3-Nacetylglucosaminyltransferase IPI00009997 ∞ IPI00009997.1 2 LRP2 Low-density lipoprotein receptor-related protein 2 precursorIPI00024292 ∞ IPI00024292.2 3 CD 14 Monocytedifferentiation antigen CD 14 precursorIPI00029260 ∞ IPI00029260.2 4 TNR Isoform 2 of Tenascin-R precursorIPI00554760, IPI00554760.1, IPI00554760.2, IPI00554760.3 ∞ 5 BTD Uncharacterized protein BTD (Fragment) IPI00744685 ∞ IPI00744685.3 6 CHL1 Isoform 1 of Neural cell adhesion molecule L1-like protein precursorIPI00783390 ∞ IPI00783390.2 7 IGLV1-40 V1-13 protein (Fragment) IPI00789259 and EMBL CDS accession number AAF62890.1 ∞ 8 COL18A1 Isoform 2 of Collagen alpha-1(XVIII) chain precursorProtein COPa ID IPI00022822 16.80 9 SEZ6 Isoform 3 ofSeizure protein 6 homolog precursorUniProt accession no. IPI00748395 10.73 10 HSPG2 Basement membrane-specific heparan sulfate proteoglycan core protein precursor EMBI-EBI accession no. IPI00024284 and IPI00024284.5 9.10 11 APLP1 amyloid precursor- like protein 1isoform 1 precursorUniProt accession no.IPI00607600 and IPI00607600.3 9.10 12 FCGBP IgGFc-binding protein precursor IPI00242956 and NP_003881.2 7.55 13 APLP2 Isoform 1 of Amyloid-like protein 2 precursorEMBL-EBI accession no. IPI00031030 and IPI00031030.1 6.75 14 TAGLN Transgelin EMBL-EBI accession no. IPI00216138 and IPI00216138.6 4.20 15 AGT Angiotensinogen precursor EMBL-EBI accession no. IPI00032220 and IPI00032220.28 3.39 16 C9 Complement component C9 precursor EMBL-EBI IPI00022395 and IPI00022395.1 3.27 17 Autotaxin isoform gamma EMBI-EBL IPI00878576 and UniProt accession no. Q13822.3 2.84 18 RBP3 Interphotoreceptor retinoid-binding protein precursor IPI00022337 and IPI00022337.1 2.71 19 Transthyretin EMBL-EBI accession no. IPI00855916 and UniProt accession no. A6XGL1.1 2.68 20 CST3;CST2 Cystatin-C precursor EMBL-EBI accession no. IPI00032293 and IPI00032293.1 2.45 21 A2M Alpha-2-macroglobufin precursor EMBL-EBI accession no. IPI00478003 and 2.10 IPI00478003.1 22 CP Ceruloplasmin precursor EMBL-EBI accession no. IPI00017601 and IPI00017601.1 1.58 - Table 4 lists three factors that are expressed at lower levels in
type 1 diabetic individuals without DR relative to those with DR. Table 7 provides factors with a statistically significant difference in expression (e.g., at least 1.5 fold) betweentype 1 diabetic individuals without DR and those with DR (see Examples 1 and 4), wherein individuals without DR have a lower level of the factors. These factors are DR risk factors. A fold decrease of "0" indicates essentially undetectable levels of the factor in a subject without DR (i.e., absence of the risk factor).Table 7: DR protective factors, exemplary accession numbers and fold decrease in type 1 diabetes individuals without DR relative to those with DRName of DR risk factor Accession Nos. Fold decrease 1 CLEC3B Putative uncharacterized protein DKFZp686H17246 EBML-EBI accession no. IPI00792115 and IPI00792115.1), 0.11 2 AFM Afamin precursor IPI00019943 0 3 CFD Complement factor D preproprotein IPI00165972 0 - Tables 3, 5 and
Figure 8 provide examples of factors that are expressed at higher levels intype 1 diabetic individuals without DN relative to those with DN. Table 8 provides factors with a statistically significant difference in expression (e.g., at least 1.5 fold) betweentype 1 diabetic individuals without DN and those with DN (see Examples 2 and 5), wherein individuals without DN have a higher level of the factors. These factors are DN protective factors.Table 8: DN protective factors, exemplary accession numbers and fold increase in type 1 diabetes individuals without DN relative to those with DNName of DN protective factor Accession Nos. Fold increase 1 HDDC3 Isoform 1 of HD domain-containingprotein 3IPI00789618 IPI00789618.3 ∞ 2 IGJ immunoglobulin J chain IPI00178926 IPI00178926.3 23.63 3 Rheumatoid factor D5 light chain (Fragment) IPI00816799 IPI00816799.1 11.00 4 BPNT1 Isoform 2 of 3(2),5-bisphosphate nucleotidase 1IPI00410215 and UniProt 095861.85 8.00 5 GNPDA1 Glucosamine-6-phosphate isomerase IPI00009305 and UniProt P46926.107 6.60 6 HPRT1 Uncharacterized protein HPRT1 IPI00873466 and NP_003881.2 4.09 7 GSTT1 Glutathione S- transferase theta 1IPI00893316 and UniProt C9JA47.9 3.48 8 BHMT Betaine--homocysteine S- methyltransferase 1IPI00004101 and UniProt Q93088.2 3.22 9 APOA1BP Isoform 2 of Apolipoprotein A-I-binding protein precursorIPI00848298 and EMBL-EBI accession no.IPI00848298.1 2.69 10 HPX Hemopexin precursor IPI00022488 EMBL-EBI accession no. IPI00022488.1 2.44 11 ALDOB Fructose-bisphosphate aldolase B IPI00218407 and UniProt Q8NHT3.51 2.36 12 AGMAT Agmatinase, mitochondrial precursor IPI00305360 and UniProt Q9BSE5.88 2.35 13 GATM Glycine amidinotransferase (L-arginine:glycine amidinotransferase) variant IPI00792191 2.13 14 PEBP 1 Phosphatidylethanolamine-bindingprotein 1IPI00219446 and EMBL-EBI accession no. IPI00219446.5 2.11 15 CS Citrate synthase, mitochondrial precursor IPI00025366 IPI00025366.4 2.06 - The bottom half of Table 5 provides examples of factors that are expressed at lower levels in
type 1 diabetic individuals without DN relative to those with DN. Table 9 provides factors with a statistically significant difference in expression betweentype 1 diabetic individuals without DN and those with DN (see Example 5), wherein individuals without DN have a lower level of the factors. These factors are DN risk factors.Table 9: DN risk factors, exemplary accession numbers and fold decrease in type 1 diabetes individuals without DN relative to those with DNName of DN risk factor Accession Nos. 1/Fold decrease Fold decrease 1 TTLL3;ARPC4 Actin-related protein 2/3complex subunit 4IPI00554811 1/0.48=2.08 0.48 IPI00554811.2 2 CTNNA1 Isoform 1 of Catenin alpha-1 1IPI00215948 1/0.42=2.38 0.42 IPI00215948.4 3 P4HB Protein disulfide- isomerase precursor IPI00010796 1/0.42=2.38 0.42 IPI00010796.1 4 RAB14 20 kDa protein IPI00646415 and EMBL-EBI accession no. IPI00646415.1 1/0.35=2.86 0.35 5 EEF1A1 Elongation factor 1-alpha IPI00025447 and EMBL-EBI accession no. IPI00025447.8 1/0.32=3.13 0.32 6 AP1B1 Isoform B ofAP-1 complex subunit beta-1 IPI00413947 and IPI00413947.2 1/0.31=3.23 0.31 7 PDIA4 Protein disulfide-isomerase A4 precursor IPI00009904 and IPI00009904.1 1/0.31=3.23 0.31 8 CALR Calreticulin precursor IPI00020599 and IPI00020599.1 1/0.28=3.57 0.28 9 ACSL1 Isoform 2 of Long-chain-fatty-acid-CoA ligase 1IPI00401448 and IPI00401448.1 1/0.27=3.70 0.27 10 PRKCSH protein kinase C substrate 80K- H isoform 2IPI00792916 and UniProt accession no. A8K318.8 1/0.23=4.35 0.23 11 PDIA3 Protein disulfide-isomerase A3 precursor IPI00025252 and IPI00025252.1 1/0.2=5.0 0.20 12 CAP1 Adenylyl cyclase-associated protein 1IPI00008274 and UniProt accession no. Q01518.110 1/0.19=5.26 0.19 13 KTN1 kinectin 1 isoform bIPI00783726 UniProt accession no. Q17RZ5.32 1/0.17=5.88 0.17 14 NDUFS2 NADH dehydrogenase [ubiquinone] iron- sulfur protein 2,mitochondrial precursor IPI00025239 1/0.14=7.14 0.14 IPI00025239.2 15 RAB6A Isoform 2 of Ras-related protein Rab-6AIPI00217943 and UniProt accession no. P20340.131 1/0.12=8.33 0.12 16 AP2A2 Adaptor-related protein complex 2,alpha 2 subunit variant (Fragment)IPI00016621 and UniProt AP2A2.2 ∞ 0.00 17 RPN1 Dolichyl-diphosphooligosaccharideprotein glycosyltransferase 67 kDa subunit precursor IPI00025874 and IPI00025874.2 ∞ 0.00 - In this table, Table 9, the fold changes were calculated from the following: the peptide numbers from individuals without DN were numerators, and the peptide numbers from individuals with DN were denominators. A fold number of "0.00" indicates that theses proteins were not detected in individuals without DN (therefore, decreased "infinitely").
- The second to last column of the Table indicates the fold "decrease" as calculated by using 1 as numerators and using the numbers of the last column as denominators.
- The present disclosure provides, inter alia, methods and compositions for diagnosing and predicting risk of developing diabetic microvascular complications (DMCs), e.g., diabetic retinopathy (DR) and or diabetic nephropathy (DN), in a subject. The methods may also be used to determine the effectiveness of a therapy for a DMC or the prognosis of a subject. A method may comprise determining the level (e.g., protein or expression level) or activity of one or more protective or risk factors of a DMC, such as the factors described herein.
- The methods include obtaining (or providing) a sample from a subject, e.g., a sample of an eye, such as vitreous, aqueous, or retinal tissue; tears; kidney tissue; plasma; or urine, and evaluating the presence and/or level of one or more biomarker described herein (e.g., in Table 2, 3, 4, 5, 6, 8, 7, 9 or
Figure 7 or8 ) in the sample, and comparing the presence and/or level with one or more reference values, e.g., a control reference value that represents a normal level of the protein, e.g., a level in an unaffected subject, and/or a disease reference that represents a level of the proteins associated with DR or DN, e.g., a level in a subject having DR or DN or an increased (high) likelihood of developing DR or DN. In a preferred embodiment, the biomarker is a DR protective factor listed in Table 6, a DN protective factor listed in Table 8, a DR risk factor listed in Table 7, or a DN risk factor listed in Table 9. - Certain methods may comprise providing a sample from a subject (e.g., a subject having diabetes, e.g., type 1 diabetes), such as plasma, a kidney sample or an eye sample, e.g., a vitreous sample; determining the level of at least one protein (factor) listed in Table 2, 3, 4, 5, 6, 8, 7, 9 or
Figure 7 or8 , preferably a factor listed in Table 6, 8, 7, or 9, in the sample; and determining whether the at least one protein is present in the sample at levels at least 50%, 75% (i.e., 1 ½ fold), 100% (i.e., 2 fold), 2.5 fold, 3 fold, 4 fold, 5 fold, 10 fold, 15 fold or higher or lower than a control value (e.g., reference level), wherein the control value is, e.g., the level of the factor in a subject having type 1 diabetes for at least 10, 15, 20, 25, or more years and who has not developed a microvascular complication, and wherein (i) a level of one or more proteins of Table 6 that is lower by, e.g., at least 50%, 75% (i.e., 1 ½ fold), 100% (i.e., 2 fold), 2.5 fold, 3 fold, 4 fold, 5 fold, 10 fold, 15 fold or more relative to a control value, e.g., the level of the factor in a subject having type 1 diabetes for at least 10, 15, 20, 25, or more years and who has not developed DR, indicates that the subject has or is likely to develop DR (or a form thereof, e.g., an advanced form of NPDR, e.g., moderate or severe NPDR; or PDR, such as active or quiescent PDR; (ii) a level of one or more proteins of Table 8 that is lower by, e.g., at least 50%, 75% (i.e., 1 ½ fold), 100% (i.e., 2 fold), 2.5 fold, 3 fold, 4 fold, 5 fold, 10 fold, 15 fold, 20 fold or higher relative to a control value, e.g., the level of the factor in a subject having type 1 diabetes for at least 10, 15, 20, 25, or more years and who has not developed DN, indicates that the subject has or is likely to develop DN; and (iii) a level of one or more proteins of Table 7 or 9 that is higher by, e.g., at least 50%, 75% (i.e., 1 ½ fold), 100% (i.e., 2 fold), 2.5 fold, 3 fold, 4 fold, 5 fold, 10 fold, 15 fold or higher relative to a control value, e.g., the level of the factor in a subject having type 1 diabetes for at least 10, 15, 20, 25, or more years and who has not developed DR or DN, respectively, indicates that the subject has or is likely to develop DR or DN, respectively. - Certain methods may comprise providing a sample from a subject (e.g., a subject having diabetes, e.g., type 1 diabetes), such as plasma, a kidney sample or an eye sample, e.g., a vitreous sample; determining the level of at least one protein (factor) listed in Table 2, 3, 4, 5, 6, 8, 7, 9 or
Figure 7 or8 , preferably a factor listed in Table 6, 8, 7 or 9, in the sample; and determining whether the at least one protein is present in the sample at levels essentially identical (e.g., at most 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100% higher or lower than) a control value (e.g., reference level), wherein the control value is, e.g., the level of the protein in a subject who has developed a microvascular complication (such as PDR, e.g., active or quiescent PDR; or NPDR, e.g., mild, moderate or severe NPDR), and wherein (i) a level of one or more proteins of Table 6 that is essentially identical to a control value, indicates that the subject has or is likely to develop DR (or a form thereof, e.g., advanced forms of NPDR, e.g., moderate or severe NPDR; or PDR, such as active or quiescent PDR); (ii) a level of one or more proteins of Table 8 that is essentially identical to a control value, e.g., the level of the factor in a subject having DN or a form thereof, indicates that the subject has or is likely to develop DN; and (iii) a level of one or more proteins of Table 7 or 9 that is essentially identical to a control value, e.g., the level of the factor in a subject having DR or DN, respectively, or a form thereof, indicates that the subject has or is likely to develop DR or DN, respectively. - In certain embodiments, the level of a DR protective factor in a subject is compared to both that in a subject who is protected, i.e., has not developed DR after at least 5, 10, 15, 20 or more years of disease, and that in a subject who has developed DR, e.g., severe NPDR or PDR, wherein a level of the DR protective factor in the subject that is significantly closer to that in a subject who is protected than to that in a subject having DR indicates that the subject is likely to be protected from developing DR, whereas a level of the DR protective factor in the subject that is significantly closer to that in a subject who has DR, e.g., severe NPDR or PDR, than to that in a subject that is protected indicates that the subject is likely to develop DR, e.g., severe NPDR or PDR.
- In certain embodiments, the level of a risk factor in a subject is compared to both that in a subject who is protected, i.e., has not developed DR after at least 5, 10, 15, 20 or more years of disease, and that in a subject who has developed DR, e.g., severe NPDR or PDR, wherein a level of the risk factor in the subject that is significantly closer to that in a subject who is protected than to that in a subject having DR indicates that the subject is likely to be protected from developing DR, whereas a level of the risk factor in the subject that is significantly closer to that in a subject who has DR, e.g., severe NPDR or PDR, than to that in a subject that is protected indicates that the subject is likely to develop DR, e.g., severe NPDR or PDR.
- In certain embodiments, the level of a DN protective factor in a subject is compared to both that of a subject who is protected, i.e., has not developed DR after at least 5, 10, 15, 20 or more years of disease, and that of a subject who has developed DN, wherein a level of the DN protective factor in the subject that is significantly closer to that in a subject who is protected than to that in a subject having DN indicates that the subject is likely to be protected from developing DN, whereas a level of the DN protective factor in the subject that is significantly closer to that in a subject who has DN, than to that of a subject that is protected indicates that the subject is likely to develop DN.
- In certain embodiments, the level of a DN risk factor in a subject is compared to both that of a subject who is protected, i.e., has not developed DR after at least 5, 10, 15, 20 or more years of disease, and that of a subject who has developed DN, wherein a level of the DN risk factor in the subject that is significantly closer to that in a subject who is protected than to that in a subject having DN indicates that the subject is likely to be protected from developing DN, whereas a level of the DN risk factor in the subject that is significantly closer to that in a subject who has DN, than to that of a subject that is protected indicates that the subject is likely to develop DN.
- A control or reference value may also be a statistically significant value obtained by, e.g., averaging the level of a particular factor present in more than 5, 10, 15, 20, 30, 40, 50, 100 or more individuals with particular characteristic, e.g., diabetes, but no DR or DN, or only mild forms thereof, such as mild NPDR.
- A control or reference value is generally factor specific, and may be the value of the factor, e.g., a statistically significant value of the factor, in (i) one or more subjects that are protected from a microvascular complication or (ii) one or more subjects that have a microvascular complication. These two types of control or reference values may be referred to "protected control value" (for the value found in protected subjects) and "disease control value" (for the value found in diseases subjects). A reference value may depend on the stage of the microvascular complication. For example, an "RBP3 control value" or "RBP3 reference value" is a control or reference value of RBP3, e.g., the value of RBP3 in one or more subjects that are protected (e.g., a subject having diabetes for over 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 years and not having developed DR; an "RBP3 protected control value") or the value of RBP3 in one or more subjects that are not protected and have or are likely to develop DR (an "RBP3 disease control value," such as "RBP3 severe NPDR control value" or "RBP3 PDR control value").
- In one embodiment, the level of RBP3 is measured in a subject, e.g., a subject with
type type 1 diabetes subjects who have not developed DR after at least 5, 10, 15, 20 or more years of disease is indicative of the likelihood of the subject to have or to develop an advanced stage of NPDR, e.g., severe, NPDR or PDR, or a poor prognostic of the DR. A method may also comprise comparing the level of RBP3 in a subject to a reference level that is the level of RBP3 (e.g., in the vitreous, retina, plasma or urine) that is present in a subject having NPDR, e.g., mild, moderate or severe NPDR, or having PDR. A subject that is found to have a similar level of RBP3 protein relative to that in a subject having severe NPDR or PDR is likely to develop a DR complication, e.g., severe NPDR or PDR. In certain embodiments, the level of RBP3 in a subject is compared to both that in a subject who is protected, i.e., has not developed DR after at least 5, 10, 15, 20 or more years of disease, and that in a subject who has developed DR, e.g., severe NPDR or PDR, wherein a level of RBP3 in the subject that is significantly closer to that in a subject who is protected than to that in a subject having DR indicates that the subject is likely to be protected from developing DR, whereas a level of RBP3 in the subject that is significantly closer to that in a subject who has DR, e.g., severe NPDR or PDR, than to that in a subject that is protected indicates that the subject is likely to develop DR, e.g., severe NPDR or PDR. - In one embodiment, the level of PEBP1 is measured in a subject, e.g., a subject with
type type 1 diabetes subjects who have not developed DN after at least 5, 10, 15, 20 or more years of disease is indicative of the likelihood of the subject to have or to develop DN or a poor prognostic of DN. A method may also comprise comparing the level of PEBP1 in a subject to a reference level that is the level of PEBP1 that is present in a subject having DN. A subject that is found to have a similar level of PEBP1 protein relative to that of a subject having DN is likely to develop a kidney complication, e.g., DN. In certain embodiments, the level of PEBP1 in a subject is compared to both that of a subject who is protected, i.e., has not developed DR after at least 5, 10, 15, 20 or more years of disease, and that of a subject who has developed DN, wherein a level of PEBP1 in the subject that is significantly closer to that in a subject who is protected than to that in a subject having DN indicates that the subject is likely to be protected from developing DN, whereas a level of RBP3 in the subject that is significantly closer to that in a subject who has DN, than to that of a subject that is protected indicates that the subject is likely to develop DN. - In certain embodiments, an increased level of a protective factor or reduced level of a risk factor is predictive of protection from a particular (or single) microvascular complication, such as DR, e.g., PDR, or DN. In certain embodiments, an increased level of a protective factor or reduced level of a risk factor is predictive of protection from more than one microvascular complication, e.g., both DR and DN. For example, an increased level of GPX3, e.g., in plasma indicates a reduced risk of a subject to develop DR or DN.
- In certain embodiments, a method comprises determining the protein level of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30 or more protective or risk factors of Tables 6, 8, 7 or 9. In certain embodiments, a method comprises determining the protein level of 1-58, 1-50, 1-45, 1-40, 1-35, 1-30, 1-25, 1-20, 1-15, 1-10, 1-5, 1-4, 1-3 or 1-2 protective or risk factors set forth in Tables 6, 8, 7 or 9. Preferred combinations of protective factors to be measured for determining the likelihood of a subject to have or to develop DR include RBP3 and or more other factors in Table 6. In certain embodiments, the level of PEDF is also measured, wherein an increased level of PEDF is protective against DR, e.g., PDR. In certain embodiments, the level of PEBP1 and that of at least one other factor, e.g., in Table 8 or 9 is measured.
- The level or concentration of protective or risk factors may be determined in a tissue sample, such as a kidney sample (e.g., renal glomeruli sample), eye vitreous or retina, or bodily fluid sample, e.g., urine, blood, plasma, or intraocular fluid. Protective or risk factors for DR may be measured in an eye sample, e.g., a sample of the vitreous, retina or intraocular fluid, of a subject. Protective or risk factors for DN may be measured in a kidney sample, e.g., a renal glomerulus sample.
- A "level of a factor" refers to the quantity or concentration of the protein or RNA (e.g., RNA) of the factor, and may also refer to the measurement of any other factor that results in the determination of the level of the factor (e.g., the measurement of the level of a metabolite of an enzyme may be a measurement of the level of the enzyme). Similarly, measurements of upstream products may also be measurements of the level of a factor.
- In certain embodiments, the level or concentration of one or more factor is measured in the blood or plasma of a subject. For example, the level of GPX3 may be measured in plasma, wherein an increased (or higher) level of GPX3 in plasma of a first subject relative to that in a second subject indicates that the first subject is less likely than the second subject to develop a kidney problem, such as DN; whereas reduced levels of GPX3 in plasma of a first subject relative to that in a second subject indicates that the first subject is more likely than the second subject to develop a kidney problem, e.g., DN (see Example 3). The level of RBP3 may be measured in plasma, wherein an increased (or higher) level of RBP3 in plasma of a first subject relative to that in a second subject indicates that the first subject is less likely than the second subject to develop a kidney problem, such as DN; whereas reduced levels of RBP3 in plasma of a first subject relative to that in a second subject indicates that the first subject is more likely than the second subject to develop a DR, e.g., PDR (see Example 6). In certain embodiments, the plasma level or concentration of both GPX3 and RBP3 is measured in a subject, e.g., to determine the likelihood of a subject to develop DR and/or DN. Any of the other factors described herein may also be measured in plasma, particularly if the factor is a soluble factor, e.g., a factor that is produced in a secreted form from a cell or a factor, e.g., a membrane bound factor, that is shed by a cell.
- A higher level of a protective factor, e.g., RBP3, or reduced level of a risk factor can also be used as a measure of the success of a treatment. For example, a
subject having type 1 diabetes who is responding positively to a diabetic treatment may have a higher level of a protective factor and/or a lower level of a risk factor relative to asubject having type 1 diabetes who is not responding to a treatment or to the value of the factor at the beginning of the treatment of the subject. Thus, an increase in the level of a protective factor and/or a decrease in the level of a risk factor in a subject withtype 1 diabetes who is being treated indicates that the subject responds positively to the treatment. - The presence and/or level of a protein can be evaluated using methods known in the art, e.g., using quantitative immunoassay methods. In some embodiments, high throughput methods, e.g., protein or gene chips as are known in the art (see, e.g., Ch. 12, Genomics, in Griffiths et al., Eds. Modern genetic Analysis, 1999,W. H. Freeman and Company; Ekins and Chu, Trends in Biotechnology, 1999, 17:217-218; MacBeath and Schreiber, Science 2000, 289(5485):1760-1763; Simpson, Proteins and Proteomics: A Laboratory Manual, Cold Spring Harbor Laboratory Press; 2002; Hardiman, Microarrays Methods and Applications: Nuts & Bolts, DNA Press, 2003), can be used to detect the presence and/or level of a biomarker listed herein (e.g., in Table 2, 3, 4, 5, 6, 8, 7, 9 or
Figure 7 or8 , preferably Table 6, 8 or 9). - In some embodiments, once it has been determined that a person has DR or DN, or has an increased risk of developing DR or DN, then a treatment, e.g., as known in the art or as described herein, can be administered.
- The compositions disclosed herein can include agents that detect or bind (e.g., that detect or bind specifically) to a biomarker described herein (e.g., in Table 2, 3, 4, 5, 6, 8, 7, 9 or
Figure 7 or8 , preferably Table 6, 8, 7 or 9). Such agents can include, but are not limited to, for example, antibodies, antibody fragments, and peptides. In some instances, the compositions can be in the form of a kit. Such kits can include one or more agents that can detect or bind (e.g., that detect or bind specifically) to one or more biomarkers described herein (e.g., one or more of the biomarkers disclosed in Table 2, 3, 4, 5, 6, 8, 7, 9 orFigure 7 or8 , preferably Table 6, 8, 7 or 9) and instructions for use. - In certain embodiments, a method comprises determining the level of a protective or risk factor in a subject. The measurement may be performed in the subject, e.g., by imaging, or on a sample obtained from a subject. If the level of the factor is determined in a sample of a subject, a method may comprise first obtaining a sample from a subject, e.g., by using a needle or other apparatus to aspirate a sample. A sample may then be sent to a laboratory for determining the level of the factor, following the doctor's instructions. If the measuring is performed in the subject, the subject may be sent to a particular department in the hospital where they handle such matters, following the doctor's instructions. The level of the factor, as determined in the laboratory or hospital is then sent back to the doctor who had ordered the measurement, or entered into a computer or data system that is accessible to the doctor. The doctor may then compare the value(s) received to reference values, which may, e.g., be present in a computer. For example, the doctor may enter the values into a computer, and the computer performs the comparison with one or more control values. The computer may also provide the conclusion regarding the likelihood of development of a microvascular complication by the subject. The doctor may then discuss the results with the subject, and choose a path forward, e.g., an appropriate treatment; the decision to re-evaluate the level of one or more factors at a later time; or to evaluate other criteria of the subjects, e.g., the presence or absence of certain symptoms.
- As used herein, "treatment" means any manner in which one or more of the symptoms of DR and/or DN are ameliorated or otherwise beneficially altered. As used herein, amelioration of the symptoms of the disorder refers to any lessening, whether permanent or temporary, lasting or transient that can be attributed to or associated with treatment by the compositions and methods of the present invention. For example, with DR, treatment can include lessening of any symptom associated with DR, including, but not limited to, blurred or distorted vision or difficulty reading, floaters, reduced vision, vision loss, pain, and/or bleeding in the eye. Similarly, with DN, treatment can include lessening of any symptom associated with DN, including, but not limited to, changes in appetite, change in sleep, protein in serum, weakness, and/or nausea.
- In some embodiments, the present disclosure provides methods for treating a microvascular complication, e.g., DR and/or DN, in a subject (e.g., a subject with diabetes (e.g.,
type 1 and/ortype 2 diabetes) by administering to the subject a therapeutically effective amount of one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more, including all) agents that increase the level or activity of one or more of the DR protective factors disclosed in Table 6 for treating or preventing DR or increase the level or activity of one or more of the DN protective factors disclosed in Table 8 for treating or preventing DN. In certain embodiments, a treatment comprises administering to a subject in need thereof a therapeutically effective amount of an agent that reduces the level or activity of a DR or DN risk factor of Table 7 or 9, respectively. An agent may increase the level or activity of a protective factor or decrease the level or activity of a risk factor by at least 50%, 100% (1 fold), 1 ½ fold, 2 fold, 3 fold, 4 fold, 5 fold, 10 fold, 15 fold, 20 fold or more. In certain embodiments, a therapeutic method comprises bringing the level or activity of a protective or risk factor essentially to its level or activity in a subject that is protected from the development of a microvascular complication. "Essentially within its level," refers to within less than 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100% of the control value. How close the level or activity can be brought to a control value depends on the particular factor, in particular on how different the level of the factor is in a protected subject versus a diseased subject. - An agent that increases the level or activity of a protective factor may be a small molecule, a protein comprising the protective factor or a biologically active variant (e.g., fragment) thereof, or a nucleic acid encoding a protein comprising the protective factor or a biologically active variant (e.g., fragment) thereof. An agent that reduces the level or activity of a risk factor may be a small molecule, an RNAi inhibitory molecule (e.g., an siRNA or hsRNA molecule), an antisense molecule, a ribozyme, or an aptamer.
- Accordingly, the present disclosure includes treatments comprising administering one or more proteins, or nucleic acid(s) encoding the one or more proteins, consisting of, consisting essentially of, or comprising the amino acid sequences, or variants thereof, that are associated with any one or more of the accession numbers of the factors disclosed in Table 6 and/or 8. For example, useful amino acid sequences can have 50%, 60%, 70%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% sequence identity to any one or more of the accession numbers disclosed in Table 6 and/or 8, provided that they retain the necessary biological activity of the factor for its protective characteristics.
- The present disclosure also contemplates use of nucleic acid sequences that encode amino acid sequences consisting of, consisting essentially of, or comprising the amino acid sequences associated with any one or more of the accession numbers disclosed in Table 6 and/or 8 or variants thereof. For example, useful nucleic acid sequences can encode an amino acid sequence with 50%, 60%, 70%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% sequence identity to any one or more of the accession numbers disclosed in Table 6 and/or 8.
- To determine the percent identity of two amino acid sequences, or of two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes). In a preferred embodiment, the length of a reference sequence aligned for comparison purposes is at least 30%, preferably at least 40%, more preferably at least 50%, even more preferably at least 60%, and even more preferably at least 70%, 80%, 90%, or 100% of the length of the reference sequence. The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position. The determination of percent identity between two amino acid sequences is accomplished using the BLAST 2.0 program. Sequence comparison is performed using an ungapped alignment and using the default parameters (Blossom 62 matrix, gap existence cost of 11, per residue gapped cost of 1, and a lambda ratio of 0.85). The mathematical algorithm used in BLAST programs is described in Altschul et al. (Nucleic Acids Res. 25:3389-3402, 1997).
- Useful proteins can also comprise amino acid sequences consisting of, consisting essentially of, or comprising the amino acid sequences associated with any one or more of the accession numbers disclosed in Table 6 and/or 8 with one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, or any range between any of the afore listed integers, or more than 100) amino acid additions, deletions or substitutions, e.g., conservative amino acid substitutions, provided that the protein retains the necessary biological activity of the factor for its protective characteristics. Conservative amino acid substitutions are known in the art.
- In some embodiments, useful proteins can include modified proteins that possess at least a portion of the activity (e.g., biological activity) of the unmodified proteins. For example, modified proteins can retain 50%, 60%, 70%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% of the activity (e.g., biological activity) of the unmodified proteins, e.g., the unmodified version of the amino acid sequences associated with any one or more of the accession numbers disclosed in Table 6 and/or 8.
- In some embodiments, useful proteins include proteins that comprise a biologically active fragment of any one or more of the factors disclosed in Table 6 and/or 8.
- In some embodiments, treatment of DR or prevention of DR can include administering one or more of the following proteins or biologically active variants thereof or nucleic acid encoding such to a subject in need of such treatment or prevention: B3GNT1 N-acetyllactosaminide beta-1,3-N-acetylglucosaminyltransferase (e.g, IPI00009997 and IPI00009997.1), LRP2 Low-density lipoprotein receptor-related
protein 2 precursor (e.g., IPI00024292 and IPI00024292.2),CD 14 Monocytedifferentiation antigen CD 14 precursor (e.g., IPI00029260 and IPI00029260.2),TNR Isoform 2 of Tenascin-R precursor (e.g., IPI00554760, IPI00554760.1, IPI00554760.2, and IPI00554760.3), BTD Uncharacterized protein BTD (Fragment) (e.g., IPI00744685 and IPI00744685.3),CHL1 Isoform 1 of Neural cell adhesion molecule L1-like protein precursor (e.g., IPI00783390 and IPI00783390.2), IGLV 1-40 V1-13 protein (Fragment) (e.g., IPI00789259 and EMBL CDS accession number AAF62890.1),COL18A1 Isoform 2 of Collagen alpha-1(XVIII) chain precursor (e.g., Protein COPa ID IPI00022822),SEZ6 Isoform 3 ofSeizure protein 6 homolog precursor (e.g., UniProt accession no. IPI00748395), HSPG2 Basement membrane-specific heparan sulfate proteoglycan core protein precursor (e.g., EMBI-EBI accession no. IPI00024284 and IPI00024284.5), APLP1 amyloid precursor-like protein 1isoform 1 precursor (e.g., UniProt accession no. IPI00607600 and IPI00607600.3), FCGBP IgGFc-binding protein precursor (e.g., IPI00242956 and NP_003881.2),APLP2 Isoform 1 of Amyloid-like protein 2 precursor (e.g., EMBL-EBI accession no. IPI00031030 and IPI00031030.1), TAGLN Transgelin (e.g., EMBL-EBI accession no. IPI00216138 and IPI00216138.6), AGT Angiotensinogen precursor (e.g., EMBL-EBI accession no. IPI00032220 and IPI00032220.28), C9 Complement component C9 precursor (e.g., EMBL-EBI IPI00022395 and IPI00022395.1), - Autotaxin isoform gamma (e.g., EMBI-EBL IPI00878576 and UniProt accession no. Q13822.3), RBP3 Interphotoreceptor retinoid-binding protein precursor (e.g., IPI00022337 and IPI00022337.1), - Transthyretin (EMBL-EBI accession no. IPI00855916 and UniProt accession no. A6XGL1.1), CST3;CST2 Cystatin-C precursor (e.g., EMBL-EBI accession no. IPI00032293 and IPI00032293.1), A2M Alpha-2-macroglobulin precursor (e.g., EMBL-EBI accession no. IPI00478003 and IPI00478003.1), and CP Ceruloplasmin precursor (e.g., EMBL-EBI accession no. IPI00017601 and IPI00017601.1). - In some embodiments, treatment of DN or prevention of DN can include administering one or more of the following proteins or biologically active variants thereof or nucleic acid encoding such to a subject in need of such treatment or prevention: IPI00789618 (e.g.,
HDDC3 Isoform 1 of HD domain-containingprotein 3, IPI00789618.3), IPI00178926 (IGJ immunoglobulin J chain and IPI00178926.3), IPI00816799 (Rheumatoid factor D5 light chain (Fragment) and IPI00816799.1), IPI00410215 (BPNT1 Isoform 2 of 3(2),5-bisphosphate nucleotidase 1 and UniProt 095861.85), IPI00009305 (GNPDA1 Glucosamine-6-phosphate isomerase and UniProt P46926.107), IPI00873466 (HPRT1 Uncharacterized protein HPRT1 and NP_003881.2), IPI00893316 (GSTT1 Glutathione S-transferase theta 1 and UniProt C9JA47.9), IPI00004101 (BHMT Betaine--homocysteine S-methyltransferase 1 and UniProt Q93088.2), IPI00848298 (APOA1BP Isoform 2 of Apolipoprotein A-1-binding protein precursor and EMBL-EBI accession no.IPI00848298.1), IPI00022488 (HPX Hemopexin precursor and EMBL-EBI accession no. IPI00022488.1), IPI00218407 (ALDOB Fructose-bisphosphate aldolase B and UniProt Q8NHT3.51), IPI00305360 (AGMAT Agmatinase, mitochondrial precursor and UniProt Q9BSE5.88), IPI00792191 (GATM Glycine amidinotransferase (L-arginine:glycine amidinotransferase) variant), IPI00219446 (PEBP1 Phosphatidylethanolamine-bindingprotein 1 and EMBL-EBI accession no. IPI00219446.5), and IPI00025366 (CS Citrate synthase, mitochondrial precursor and IPI00025366.4). - In certain embodiments, treatment of DR or prevention of DR can include administering an agent that inhibits or reduces the expression or activity of one or more of: CLEC3B Putative uncharacterized protein DKFZp686H17246 (e.g., EBML-EBI accession no. IPI00792115 and IPI00792115.1), AFM Afamin precursor (e.g., IPI00019943), CFD Complement factor D preproprotein (e.g., IPI00165972), and PTGDS in a subject.
- In some embodiments, treatment of DN or prevention of DN can include administering an agent that inhibits or reduces the expression or activity of one or more of: IPI00554811 (TTLL3;ARPC4 Actin-related
protein 2/3complex subunit 4 and IPI00554811.2), IPI00215948 (CTNNA1 Isoform 1 of Catenin alpha-1 and IPI00215948.4), IPI00010796 (P4HB Protein disulfide-isomerase precursor and IPI00010796.1), IPI00646415 (RAB 14 20 kDa protein and EMBL-EBI accession no. IPI00646415.1), IPI00025447 (EEF1A1 Elongation factor 1-alpha and EMBL-EBI accession no. IPI00025447.8), IPI00413947 (AP1B1 Isoform B of AP-1 complex subunit beta-1 and IPI00413947.2), IPI00009904 (PDIA4 Protein disulfide-isomerase A4 precursor and IPI00009904.1), IPI00020599 (CALR Calreticulin precursor and IPI00020599.1), IPI00401448 (ACSL1 Isoform 2 of Long-chain-fatty-acid--CoA ligase 1 and IPI00401448.1), IPI00792916 (PRKCSH protein kinase C substrate 80K-H isoform 2 and UniProt accession no. A8K318.8), IPI00025252 (PDIA3 Protein disulfide-isomerase A3 precursor and IPI00025252.1), IPI00008274 (CAP1 Adenylyl cyclase-associatedprotein 1 and UniProt accession no. Q01518.110), IPI00783726 (KTN1 kinectin 1 isoform b and UniProt accession no. Q17RZ5.32), IPI00025239 (NDUFS2 NADH dehydrogenase [ubiquinone] iron-sulfur protein 2, mitochondrial precursor and IPI00025239.2), IPI00217943 (RAB6A Isoform 2 of Ras-related protein Rab-6A and UniProt accession no. P20340.131), IPI00016621 (AP2A2 Adaptor-relatedprotein complex 2,alpha 2 subunit variant (Fragment) and UniProt AP2A2.2), and IPI00025874 (RPN1 Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 67 kDa subunit pre and IPI00025874.2) in a subject. - In certain embodiments, RBP3, e.g., human RBP3, or a biologically active variant thereof is administered to a subject having or likely to develop DR, e.g., PDR, or to protect the cells of a subject from high glucose exposure. "RBP3" refers to "
retinol binding protein 3, interstitial," and is also referred to as interphotoreceptor retinoid-binding protein, IRBP, D10S64, D10S65, D10S66, and RBPI. As indicated in the NCBI Gene database, RBP3 is a large glycoprotein known to bind retinoids and found primarily in the interphotoreceptor matrix of the retina between the retinal pigment epithelium and the photoreceptor cells. It is thought to transport retinoids between the retinal pigment epithelium and the photoreceptors, a critical role in the visual process. The amino acid sequence of human RBP3 can be divided into four contiguous homology domains with 33-38% identity. The precursor of the human RBP3 protein is 1247 aa long and has the amino acid sequence set forth in GenBank Accession No. NP_002891. The nucleotide and amino acid sequences of human RBP3 are set forth as SEQ ID NOs: 1 and 2, respectively, and shown inFigure 9 . The signal peptide of human RBP3 corresponds to amino acids 1-17. The mature protein consists of amino acids 18-1247. The protein comprises four domains referred to as Peptidase_S41_IRBP regions. These domains are located atamino acids 27 to 318 of SEQ ID NO: 2, amino acids 329 to 626 of SEQ ID NO: 2, amino acids 639 to 931 of SEQ ID NO: 2, and amino acids 940 to 1226 of SEQ ID NO: 2. The xenopus RBP3 has been crystalized and its structure solved (Ghosh D et al, Mol Vis. 2007 Dec 13;13:2275-81), and from sequence homology some regions can be predicted. The authors conclude that the data may indicate that the retinol-binding site is restricted to one of the four modules, or to an intramodule site defined by multiple modules, consistent with the notion that not all four modules are functionally equivalent as the homology modeling results indicated. - A homozygous missense mutation (pAsp1080Asn) in human RBP3 has been reported to be associated with retinitis pigmentosa (den Hollander et al. Invest. Ophthalmol. Vis. Sci. April 2009 vol. 50 no. 4 1864-187), and the authors predict that this residue participates in the retinol binding domain of the human RBP3 protein.
- The nucleotide sequence of a cDNA encoding full length human RBP3 precursor (SEQ ID NO: 1) consists of 4289 nucleotides, wherein nucleotides 115 to 3858 encode SEQ ID NO: 2. The signal peptide is encoded by nucleotides 115 to 165, and the mature protein is encoded by nucleotides 166 to 3855 of SEQ ID NO: 1.
- Biologically active variants of the full length human RBP3 protein (having SEQ ID NO: 2 or the mature form thereof) that may be used in therapeutic methods for treating DR include those comprising an amino acid sequence that comprises fewer amino acids than SEQ ID NO: 2 or the mature form thereof, and contains, e.g., at most 5, 10, 20, 30, 50, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000 or more, fewer amino acids. A biologically active fragment of human RBP3 may comprise 1, 2, 3 or all 4 homology domains. Other biologically active fragments of human RBP3 include those that retain the ability to bind to retinol or other lipid, e.g., they comprise Asp1080.
- Biologically active variants of human RBP3 also include full length immature and mature forms of human RBP3 or fragments thereof that comprise an amino acid sequence that differs from SEQ ID NO: 2 or fragment thereof in at most 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50 or 100 amino acid deletions, additions or substitutions, such as conservative amino acid substitutions. Biologically active variants of a human RBP3 protein may also include variants that are at least 70%, 80%, 85%, 90%, 95%, 97%, 98% or 99% identical to the full length mature or precursor human RBP3 protein or a fragment thereof.
- Biologically active variants of human PEBP1 also include full length immature and mature forms of human PEBP1 or fragments thereof that comprise an amino acid sequence that differs from the naturally occurring sequence (e.g., SEQ ID NO: 4; GenBank Accession No. NP_002558; encoded by a nucleotide sequence having GenBank Accession No. NM_002567 and set forth herein as SEQ ID NO: 3;
Figure 17 ) or fragment thereof in at most 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50 or 100 amino acid deletions, additions or substitutions, such as conservative amino acid substitutions. Biologically active variants of a human PEBP1 protein may also include variants that are at least 70%, 80%, 85%, 90%, 95%, 97%, 98% or 99% identical to the full length mature or precursor human PEBP1 protein or a fragment thereof. - The present disclosure also includes fusion proteins comprising any one or more amino acid sequence disclosed in Table 6 and/or 8 in combination with a moiety that increases the stability of the fusion protein in vivo (e.g., polyethelene glycol (PEG)) and/or that increases transport of the fusion protein to the therapeutic target (e.g., the eye and/or the kidney).
- As further described herein, protein may be administered systemically or locally. For example, a protein for treating or preventing DR, e.g., human RBP3 or a biologically active variant thereof, may be administered directly into the eye, e.g., in the vitreous, e.g., by injection. For example, a protein may be injected into the eye using the same or a similar methodology as that used for administered LUCENTIS or AVASTIN to the eye of a subject. An agent for treating or preventing DR may also be administered to the eye in the form of drops or a periocular injection (peribulbar or subconjunctival).
- In certain embodiments, a protein for treating DR, e.g., human RBP3 or a biologically active variant thereof, may be administered with another agent for treating or preventing DR, such as LUCENTIS or AVASTIN. Two or more pharmaceutical agents may be administered simultaneously or sequentially. They may be present in one pharmaceutical composition or more than one pharmaceutical composition.
- Systemic administration is also expected to be functional, e.g., for treating DR, as the retinal blood barrier is leaky in diabetic subjects. In particular, regarding RBP3, as it does not appear to be expressed in any other tissues than the eye, systemic administration is not expected to cause significant toxicity.
- Other methods of treatment comprise preventing the degradation of a factor listed in Table 6 or 8, such as RBP3. Yet other methods include administering an agent that increases the expression of a factor in Table 6 or 8 or that reduces the expression of a risk factor listed in Table 7 or 9. An agent may be a small molecule, e.g., a small molecule that activates the promoter of the factor. In certain embodiments, an agent for treating a subject as described herein is an agent that increases the activity of a factor in Table 6 or 8 or reduces the activity of a factor in Table 7 or 9.
- The present disclosure also contemplates the use of gene therapy methods, e.g., to administer a nucleic acid encoding one or more of the factors (e.g., protective factors) or nucleic acids inhibiting the expression or activity of a DR or DN risk factor disclosed herein to a subject. For example, nucleic acids encoding a protein disclosed in Table 6 and/or 8, or a variant thereof, or a nucleic acid encoding the protein that increases the expression, level or activity, of one or more of the factors disclosed in Tables 6 and/or 8 can be incorporated into a gene construct to be used as a part of a gene therapy protocol.
- The disclosure includes targeted expression vectors for in vivo transfection and expression of a polynucleotide that encodes a polypeptide disclosed in Table 6 and/or 8, or an active fragment thereof, in particular cell types, for cells of the eye and/or kidney. Expression constructs of such components can be administered in any effective carrier, e.g., any formulation or composition capable of effectively delivering the component gene to cells in vivo. Approaches include insertion of the gene in viral vectors, including recombinant retroviruses, adenovirus, adeno-associated virus, lentivirus, and herpes simplex virus-1, or recombinant bacterial or eukaryotic plasmids. Viral vectors transfect cells directly; plasmid DNA can be delivered naked or with the help of, for example, cationic liposomes (lipofectamine) or derivatized (e.g., antibody conjugated), polylysine conjugates, gramacidin S, artificial viral envelopes or other such intracellular carriers, as well as direct injection of the gene construct or CaPO4 precipitation carried out in vivo.
- A preferred approach for in vivo introduction of nucleic acid into a cell is by use of a viral vector containing nucleic acid, e.g., a cDNA. Infection of cells with a viral vector has the advantage that a large proportion of the targeted cells can receive the nucleic acid. Additionally, molecules encoded within the viral vector, e.g., by a cDNA contained in the viral vector, are expressed efficiently in cells that have taken up viral vector nucleic acid.
- Retrovirus vectors and adeno-associated virus vectors can be used as a recombinant gene delivery system for the transfer of exogenous genes in vivo, particularly into humans. These vectors provide efficient delivery of genes into cells, and the transferred nucleic acids are stably integrated into the chromosomal DNA of the host. The development of specialized cell lines (termed "packaging cells") which produce only replication-defective retroviruses has increased the utility of retroviruses for gene therapy, and defective retroviruses are characterized for use in gene transfer for gene therapy purposes (for a review see Miller, Blood 76:271 (1990)). A replication defective retrovirus can be packaged into virions, which can be used to infect a target cell through the use of a helper virus by standard techniques. Protocols for producing recombinant retroviruses and for infecting cells in vitro or in vivo with such viruses can be found in Ausubel, et al., eds., Current Protocols in Molecular Biology. Greene Publishing Associates, (1989), Sections 9.10-9.14, and other standard laboratory manuals. Examples of suitable retroviruses include pLJ, pZIP, pWE and pEM which are known to those skilled in the art. Examples of suitable packaging virus lines for preparing both ecotropic and amphotropic retroviral systems include ΨCrip, ΨCre, Ψ2 and ΨAm. Retroviruses have been used to introduce a variety of genes into many different cell types, including epithelial cells, in vitro and/or in vivo (see for example Eglitis, et al. (1985) Science 230:1395-1398; Danos and Mulligan (1988) Proc. Natl. Acad. Sci. USA 85:6460-6464; Wilson et al. (1988) Proc. Natl. Acad. Sci. USA 85:3014-3018; Armentano et al. (1990) Proc. Natl. Acad. Sci. USA 87:6141-6145; Huber et al. (1991) Proc. Natl. Acad. Sci. USA 88:8039-8043; Ferry et al. (1991) Proc. Natl. Acad. Sci. USA 88:8377-8381; Chowdhury et al. (1991) Science 254:1802-1805; van Beusechem et al. (1992) Proc. Natl. Acad. Sci. USA 89:7640-7644; Kay et al. (1992) Human Gene Therapy 3:641-647; Dai et al. (1992) Proc. Natl. Acad. Sci. USA 89:10892-10895; Hwu et al. (1993) J. Immunol. 150:4104-4115;
U.S. Patent No. 4,868,116 ;U.S. Patent No. 4,980,286 ;PCT Application WO 89/07136 PCT Application WO 89/02468 PCT Application WO 89/05345 PCT Application WO 92/07573 - Another viral gene delivery system useful in the present methods utilizes adenovirus-derived vectors. The genome of an adenovirus can be manipulated, such that it encodes and expresses a gene product of interest but is inactivated in terms of its ability to replicate in a normal lytic viral life cycle. See, for example, Berkner et al., BioTechniques 6:616 (1988); Rosenfeld et al., Science 252:431-434 (1991); and Rosenfeld et al., Cell 68:143-155 (1992). Suitable adenoviral vectors derived from the adenovirus
strain Ad type 5 d1324 or other strains of adenovirus (e.g., Ad2, Ad3, or Ad7 etc.) are known to those skilled in the art. Recombinant adenoviruses can be advantageous in certain circumstances, in that they are not capable of infecting non-dividing cells and can be used to infect a wide variety of cell types, including epithelial cells (Rosenfeld et al., (1992) supra). Furthermore, the virus particle is relatively stable and amenable to purification and concentration, and as above, can be modified so as to affect the spectrum of infectivity. Additionally, introduced adenoviral DNA (and foreign DNA contained therein) is not integrated into the genome of a host cell but remains episomal, thereby avoiding potential problems that can occur as a result of insertional mutagenesis in situ, where introduced DNA becomes integrated into the host genome (e.g., retroviral DNA). Moreover, the carrying capacity of the adenoviral genome for foreign DNA is large (up to 8 kilobases) relative to other gene delivery vectors (Berkner et al., supra; Haj-Ahmand and Graham, J. Virol. 57:267 (1986). - Yet another viral vector system useful for delivery of nucleic acids is the adeno-associated virus (AAV). Adeno-associated virus is a naturally occurring defective virus that requires another virus, such as an adenovirus or a herpes virus, as a helper virus for efficient replication and a productive life cycle. (For a review see Muzyczka et al., Curr. Topics in Micro. and Immunol.158:97-129 (1992). It is also one of the few viruses that may integrate its DNA into non-dividing cells, and exhibits a high frequency of stable integration (see for example Flotte et al., Am. J. Respir. Cell. Mol. Biol. 7:349-356 (1992); Samulski et al., J. Virol. 63:3822-3828 (1989); and McLaughlin et al., J. Virol. 62:1963-1973 (1989). Vectors containing as little as 300 base pairs of AAV can be packaged and can integrate. Space for exogenous DNA is limited to about 4.5 kb. An AAV vector such as that described in Tratschin et al., Mol. Cell. Biol. 5:3251-3260 (1985) can be used to introduce DNA into cells. A variety of nucleic acids have been introduced into different cell types using AAV vectors (see for example Hermonat et al., Proc. Natl. Acad. Sci. USA 81:6466-6470 (1984); Tratschin et al., Mol. Cell. Biol. 4:2072-2081 (1985); Wondisford et al., Mol. Endocrinol. 2:32-39 (1988); Tratschin et al., J. Virol. 51:611-619 (1984); and Flotte et al., J. Biol. Chem. 268:3781-3790 (1993).
- In addition to viral transfer methods, such as those illustrated above, non-viral methods can also be employed to cause expression of a nucleic acid compound described herein (e.g., a nucleic acid encoding a polypeptide disclosed in Table 6 or 8, or an active fragment thereof, and/or a nucleic acid that increases the expression and/or activity of a polynucleotide that encodes a polypeptide disclosed in Table 6 or 8 or a nucleic acid that inhibits a protein in Table 7 or 9) in the tissue of a subject. Typically non-viral methods of gene transfer rely on the normal mechanisms used by mammalian cells for the uptake and intracellular transport of macromolecules. In some embodiments, non-viral gene delivery systems can rely on endocytic pathways for the uptake of the subject gene by the targeted cell. Exemplary gene delivery systems of this type include liposomal derived systems, poly-lysine conjugates, and artificial viral envelopes. Other embodiments include plasmid injection systems such as are described in Meuli et al., J. Invest. Dermatol. 116(1):131-135 (2001); Cohen et al., Gene Ther. 7(22):1896-905 (2000); or Tam et al., Gene Ther. 7(21):1867-74 (2000).
- In some embodiments, an agent, e.g., a gene encoding a factor described herein, e.g., a polynucleotide that encodes a polypeptide disclosed in Table 6 or 8, or an active fragment thereof, or an agent that inhibits the expression or activity of a factor in Table 7 or 9, is entrapped in liposomes bearing positive charges on their surface (e.g., lipofectins), which can be tagged with antibodies against cell surface antigens of the target tissue (Mizuno et al., No Shinkei Geka 20:547-551 (1992);
PCT publication WO91/06309 Japanese patent application 1047381 EP-A-43075 - In clinical settings, the gene delivery systems for the therapeutic gene can be introduced into a subject by any of a number of methods, each of which is familiar in the art. For instance, a pharmaceutical preparation of the gene delivery system can be introduced systemically, e.g., by intravenous injection, and specific transduction of the protein in the target cells will occur predominantly from specificity of transfection, provided by the gene delivery vehicle, cell-type or tissue-type expression due to the transcriptional regulatory sequences controlling expression of the receptor gene, or a combination thereof. In other embodiments, initial delivery of the recombinant gene is more limited, with introduction into the subject being quite localized. For example, the gene delivery vehicle can be introduced by catheter (see
U.S. Patent 5,328,470 ) or by stereotactic injection (e.g., Chen et al., PNAS USA 91: 3054-3057 (1994)). - The pharmaceutical preparation of the gene therapy construct can consist essentially of the gene delivery system in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is embedded. Alternatively, where the complete gene delivery system can be produced intact from recombinant cells, e.g., retroviral vectors, the pharmaceutical preparation can comprise one or more cells, which produce the gene delivery system.
- In some embodiments, the present disclosure includes the use of agonists of any one or more of the factors disclosed in Tables 6 and/or 8. In some embodiments, suitable agonists can increase the expression and/or activity of one or more of the factors disclosed in Tables 6 and/or 8, e.g., by about 2-fold, 3-fold, 4-fold, 5-fold, or more.
- In some embodiments, the present disclosure includes the use of antagonists of any one or more of the factors disclosed in Tables 7 and/or 9. In some embodiments, suitable antagonists can decrease the expression and/or activity of one or more of the factors disclosed in Tables 7 and/or 9, e.g., by about 2-fold, 3-fold, 4-fold, 5-fold, or more.
- Many of the factors disclosed herein are referenced by the International Protein Index (IPI) number assigned to them. The sequences associated with each of the disclosed IPI numbers are publically available and can be obtained and/or viewed, for example, using the European Institute for Bioinformatics website available at world wide web address ebi.ac.uk. Other suitable websites are also known in the art.
- The term "subject" is used throughout the specification to describe an animal, human or non-human, to whom treatment according to the methods described herein is provided.
- The methods disclosed herein can include selecting a subject for treatment. For example, a subject can be selected if the subject has or is at risk for developing DR and/or DN, e.g., a subject having diabetes, e.g.,
type 1 ortype 2 diabetes, or a subject who is prediabetic, e.g., having metabolic syndrome, insulin resistance, hyperglycemia, hyperlipidemia or a subject who is overweight or obese, e.g., having a BMI ≥ 25. In some instances, a subject can be selected if the subject has or is at risk for developingtype 1 and/ortype 2 diabetes. In some instances, a subject can be selected if the subject is taking or will take insulin, e.g., to treat diabetes. - One or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more, including all) of the agents, such as factors disclosed herein (e.g., disclosed in Tables 6 and/or 8) or agents inhibiting a factor of Table 7 or 9, can be administered alone or as a pharmaceutical composition (disclosed below) using any mode of administration, e.g., including any mode of administration that results in a therapeutically effective level in the eye (for DR) and/or the kidney (for DN). In some instances, a therapeutically effective level is an amount or level that results in one or more of the symptoms of DR and/or DN being ameliorated or otherwise beneficially altered. For the treatment of DR, an exemplary route of administration can include local administration into or onto the eye. For the treatment of DN, an exemplary route of administration can include local administration to the kidney. Other exemplary modes of administration suitable for either DR or DN include, but are not limited to, oral, parenteral, inhalation (e.g., as a spray), topical, rectal, nasal, buccal, vaginal, and/or via an implanted reservoir.
- The term parenteral as used herein includes subcutaneous, intracutaneous, intravenous, intramuscular, intra¬articular, intraarterial, intrasynovial, intrasternal, intrathecal, intralesional and intracranial injection or infusion techniques. Alternatively or in addition, the present invention may be administered according to any of the Food and Drug Administration approved methods, for example, as described in CDER Data Standards Manual, version number 004 (which is available at fda.give/cder/dsm/DRG/drg00301.htm). Where application over a period of time is advisable or desirable, the compositions of the invention can be placed in sustained released formulations (e.g., hydrogels) or implantable devices (e.g., implantable pumps).
- One or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more, including all) of the agents, e.g., factors disclosed herein (e.g., disclosed in Tables 6 and 8) or inhibitors of factors in Table 7 or 9, can be formulated in or as pharmaceutical compositions. Such pharmaceutical compositions can contain any conventional non-toxic pharmaceutically-acceptable carriers, adjuvants or vehicles. In some cases, the pH of the formulation may be adjusted with pharmaceutically acceptable acids, bases or buffers to enhance the stability of the formulated compound or its delivery form.
- In some cases, pharmaceutical compositions containing one or more factors can be formulated according to the intended method of administration.
- Pharmaceutical compositions containing one or more factors can be formulated in a conventional manner using one or more physiologically acceptable carriers or excipients. The nature of the pharmaceutical compositions for administration is dependent on the mode of administration and can readily be determined by one of ordinary skill in the art. In addition, methods for making such formulations are well known and can be found in, for example, Remington's Pharmaceutical Sciences, 18th Ed., Gennaro, ed., Mack Publishing Co., Easton, Pa., 1990. In some embodiments, the pharmaceutical composition is sterile or sterilizable.
- Pharmaceutical compositions featured in the invention can contain carriers or excipients, many of which are known to skilled artisans. Excipients that can be used include buffers (for example, citrate buffer, phosphate buffer, acetate buffer, and bicarbonate buffer), amino acids, urea, alcohols, ascorbic acid, phospholipids, polypeptides (for example, serum albumin), EDTA, sodium chloride, liposomes, mannitol, sorbitol, water, and glycerol.
- In some embodiments, pharmaceutical compositions can be presented in unit dosage form, for example, in ampoules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the composition may be in powder form for constitution with a suitable vehicle, for example, sterile pyrogen-free water, before use. Agents that enhance delivery into a cell can be used as well, e.g., liposomes or micelles.
- In addition to the formulations described previously, the compositions can also be formulated as a depot preparation. Thus, for example, the compositions can be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
- Pharmaceutical compositions can also take the form of tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (for example, pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (for example, lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (for example, magnesium stearate, talc or silica); disintegrants (for example, potato starch or sodium starch glycolate); or wetting agents (for example, sodium lauryl sulphate). The tablets can be coated by methods well known in the art. Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (for example, sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (for example, lecithin or acacia); non-aqueous vehicles (for example, almond oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (for example, methyl or propyl-p-hydroxybenzoates or sorbic acid). The preparations may also contain buffer salts, flavoring, coloring and sweetening agents as appropriate. Preparations for oral administration may be suitably formulated to give controlled release of the active compound.
- The methods herein contemplate administration of an effective amount of compound or compound composition to achieve the desired or stated effect. Toxicity and therapeutic efficacy of the compounds and pharmaceutical compositions described herein can be determined by standard pharmaceutical procedures, using either cells in culture or experimental animals to determine the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and can be expressed as the ratio LD50/ED50. Polypeptides or other compounds that exhibit large therapeutic indices are preferred.
- Data obtained from cell culture assays and further animal studies can be used in formulating a range of dosage for use in humans. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For any compound used in the methods described herein, the therapeutically effective dose can be estimated initially from cell culture assays. A dose can be formulated in animal models to achieve a circulating plasma concentration range that includes the IC50 (that is, the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans.
- The formulations and routes of administration can be tailored to the disease or disorder being treated, and for the specific human being treated. A subject can receive a dose of the agent once or twice or more daily for one week, one month, six months, one year, or more. The treatment can continue indefinitely, such as throughout the lifetime of the human. Treatment can be administered at regular or irregular intervals (once every other day or twice per week), and the dosage and timing of the administration can be adjusted throughout the course of the treatment. The dosage can remain constant over the course of the treatment regimen, or it can be decreased or increased over the course of the treatment.
- Generally the dosage facilitates an intended purpose for both prophylaxis and treatment without undesirable side effects, such as toxicity, irritation or allergic response. Although individual needs may vary, the determination of optimal ranges for effective amounts of formulations is within the skill of the art. Human doses can readily be extrapolated from animal studies (Katocs et al., ). Generally, the dosage required to provide an effective amount of a formulation, which can be adjusted by one skilled in the art, will vary depending on several factors, including the age, health, physical condition, weight, type and extent of the disease or disorder of the recipient, frequency of treatment, the nature of concurrent therapy, if required, and the nature and scope of the desired effect(s) (Nies et al., ).
- The methods can also include monitoring or evaluating the subject during and after treatment to determine the efficacy of the treatment, and, if necessary, adjusting treatment (e.g., by altering the composition, by increasing the dose of a single administration of the composition, by increasing the number of doses of the composition administered per day, and/or by increasing the number of days the composition is administered) to improve efficacy. Monitoring or evaluating the subject can include identifying a suitable marker of disease prior to commencing treatment and optionally recording the marker, and comparing the identified or recorded marker to the same marker during and/or after treatment. Suitable markers can include one or more symptoms of the subject's disease. Suitable markers also include one or more of the factors described in Tables 6, 8, 7 and 9. Adjustment of treatment would be recommended where the marker is a symptom of disease and comparison of the marker during or after treatment with the marker prior to treatment revealed either no change in the marker or an increase in the marker. Conversely, adjustment of treatment may not be required using the same markers where an increase in the marker is observed.
- Evidence that diabetic retinal pathologies can be halted has been documented by the Joslin 50-Year Medalist Study (Keenan et al., Diabetes Care. 2007 Aug;30(8): 1995-7. Epub 2007 May 16). Population characteristics for these subjects are shown in Table 1.
Table 1- Characteristics of Medalist Study participants. % (n); mean ± std dev Male(%) 47.0% (192) HbA1c(%) 7.3% ± 1.1 Age (years) 67.2 ± 7.4 Age at diagnosis (years) 11.0 ± 6.5 Duration (years) 56.2 ± 5.8 BMI (kg/m2) 26.0 ± 5.1 C-peptide (nmol/L) 0.07 ± 0.12 Cholesterol (mmol/L) 4.2 ± 0.9 HDLc (mmol/L) 1.6 ± 0.5 LDL(mmol/L) 2.2 ± 0.6 Triglycerïdes (mmol/l) 0.9 ± 0.5 Insulin dose (u/kg) 0.46 ± 02 Family History Any DM 29.7 (122) T1 DM 12.9 (53) DR3 38.8 (116) DR4 52.0 (156) DR3 or DR4 93.7 (295) DR3/4 39.1 (118) IA2 or GAD 29.7 (111) IA2 14.9 (56) GAD 18.4 (69) PDR 55 (163) Microalbuminuria (ACR<7.91) 13.1 (45) Neuropathy (MNSI>2) 60.6 (183) CVD 48.3 (160) type 1 diabetes (T1DM) by clinical exam, medical history and extensive chemistries. - Retinal pathology was documented by dilated fundus examination and fundus photography. The degree of renal disease was assessed through measurements of albumin, creatinine, cystatin C and estimated glomerular filtration rate (eGFR). After characterizing over 500 Medalists, a bimodal distribution of DR was observed with 50% of the Medalists having none to moderate nonproliferative DR and 50% having quiescent PDR (
Fig. 1 and Table 1). Surprisingly, standard risk factors, including duration of diabetes and HbAlC levels, were not associated with severity. - A subset of 97 Medalists has been followed with multiple ophthalmic examinations. Analysis of DR progression showed that 47.4% of eyes without proliferative DR (PDR) at baseline progressed to PDR, with a median time to progression to PDR of 38.4 years. The majority of Medalists who did not progress to PDR developed mild to moderate non-proliferative DR (NPDR) over a median follow-up of 20.6 years. Interestingly, of the eyes that did not develop PDR, all but one eye stopped progressing after 17 years of follow-up (
Fig 2 ). Over the last two years we have been collaborating with the network for Pancreatic Organ Donors with Diabetes (nPOD) to procure tissues from Medalists after they have passed away. Organ donations have been obtained from 11 Medalists, including whole eyes, kidneys, pancreas and skin. During their initial study visit we obtained specimens of DNA, serum, plasma, and urine. - In the present experiments, samples were taken from eight eyes: three with no to moderate NPDR, four with PDR, and one ungradeable (due to scatter laser performed for nondiabetic pathology) as determined by grading of fundus photographs. Retinal pathology was assessed using standard methods. For proteomic analysis, retinal and vitreous specimens were isolated and isolated using mass spectrometry methods as previously described (Gao et al., J Proteome Res. 2008;7:2516-25; Gao et al., Nat Med. 2007;13:181-8). Initial analysis of these eight eyes by mass spectrometry identified over 450 proteins. Based on a minimum 1.5 fold increase and significance level of at least 0.1, 26 proteins were found to be higher in the vitreous of Medalists who have no to moderate NPDR compared to those with PDR. Interestingly, pathway analysis indicated that 6/26 of these proteins have anti-angiogenic actions, whereas, only 1/26 have anti-oxidative stress properties and 8/26 are adhesion proteins. (Table 2).
Table 2. Protective genes or proteins in Eye vitreous G-Protein APLP2 amyloid beta (A4) precursor-like protein 2 G-protein coupled receptor protein Signaling pathway Prostaglandin Enzyme PTGDS prostaglandin D2 synthase 21kDa (brain) glutathione-independent prostaglandin D synthase, PGH2-> PGD2 also fatty acid biosynthetic process associate with Basement Membrane B3GNT1 UDP-GlcNAc:betaGal beta-1,3-N- acetylglucosaminyltransferase 1type II transmembrane protein, integral to Golgi membrane Complement C5 Complement C5 C6 Complement C6 A2M Alpha-2-macroglobulin a protease inhibitor and cytokine transporter Growth/ tumor suppressor gene DKK3 WIF1 Ig superfamily Rheumatoid factor C6 light chain IGLV1-40 Ig kappa chain V- IV region Len IGHM Cytokine FAM3C SERPINF1(PEDF) A2M Adhesion protein CLSTN1 SPARCL1 CDH2 cadherin 2, type 1, N-cadherinSPP1 secreted phosphoprotein 1ECM-receptor interaction, Focal adhesion, Toll-like receptor signaling pathway, Signaling by PDGF, Integrin cell surface interactions, osteoblast differentiation NRCAM APP Protease inhibition A2M Alpha-2-macroglobulin a protease inhibitor and cytokine transporter SERPINF1(PEDF) PCSK1N CST3 cystatin C CPE Carboxypeptidase E APP serine-type endopeptidase inhibitor activity Lipid metabolism ASAH1 Acid ceramidase APOE Oxidative Stress GPX3 Not grouped ABI3BP CUTA SEZ - Clinical characterization of the Medalists and histopathologic and proteomic analysis of their tissues has enabled us to identify new biomarkers for progression to PDR for diabetic patients with shorter duration disease. Furthermore, these protective factors against the progression of DR are potential therapeutic targets.
- These potential "protective" and "risk" factors identified from the vitreous and retinas of Medalist patients are secondarily screened using (intraocular) aqueous fluid and plasma from a population of both
type - Nine kidney samples from the Medalists were analyzed by mass spectrometry as previously described (Gao et al., J Proteome Res. 2008;7:2516-25; Gao et al. Nat Med. 2007;13:181-8). Using the results from the proteomic analyses and correlated pathology derived from the renal glomeruli, we found that the expression of 14 proteins are significantly (1.5 fold) greater in kidneys without disease vs. those with class II and III levels of nephropathy. The proteins are listed in Table 3.
Table 3. Protective genes or proteins in Renal Glomeruli Lipid Metabolism APOA1BP Isoform 2 of Apolipoprotein A-1-binding protein precursor interacts with apolipoprotein A-I (apoA-I), the major apolipoprotein of high-density lipoproteins (HDLs) Oxidation reduction/ Oxidative Stree Isoform 1 of MOSC domain-containing protein 2, mitochondrialMOSC2 precursor (mt) HPX Hemopexin precursor glycoprotein, binds heme GPX3 Glutathione peroxidase 3 precursor detoxification of hydrogen peroxide GSTT1 Glutathione S- transferase theta 1PRDX1 peroxiredoxin 1 antioxidant enzymes, reduce hydrogen peroxide and alkyl hydroperoxides Isoform 2 of Hydroxyacyl-coenzyme A dehydrogenase, HADH mitochondrial precursor (mt) also fatty acid metabolism SCCPDH saccharopine dehydrogenase (putative) oxidoreductase activity (mt) Purine metabolism HPRT1 hypoxanthine phosphoribosyltransferase 1 Basement membrane COL18A1 collagen, type XVIII, alpha 1Mitochondrial metabolism/ enymes MOSC2 HADH SCCPDH GATM Glycine amidinotransferase (L-arginine:glycine amidinotransferase) Metabolism of amino acids and derivatives AGMAT agmatine ureohydrolase (agmatinase) Metabolism of amino acids and derivatives CS citrate synthase Glucose metabolism GNPDA1 glucosamine-6- phosphate deaminase 1Amino sugar and nucleotide sugar metabolism - Validation of the proteins identified through comparison of those with and without DN will be done using samples of urine, plasma and serum from the Joslin Natural History of Microalbuminuria Studies. The validation study is a case-control testing the hypothesis of a significantly lower level of the factor of interest being present in fast progressors, defined as those who have had a greater than 7% eGFR loss of per year over a 10 year period within 15 year duration compared to those with chronic
kidney disease classifications - Candidates identified by our proteomic analysis of the vitreous and kidney are measured in the plasma of normal and
type 1 diabetic patients to validate the relationship with protection against DR/DN, and to examine whether there is a temporal relationship with progression of DR/DN. - GPX3, which was identified as a biomarker in both the vitreous and kidney, a secreted enzyme and is involved in neutralizing hydroxides and preventing lipid peroxidation, was measured plasma GPX3 levels by ELISA method in 40 Medalists and a positive correlation was observed between the level of GPX3 and estimated GFR calculated by cystatin C (
Fig. 3 ). - The results described herein are corroborated by reports in the literature. PEDF, an anti-angiogenic protein representing a major pathway of protective factors identified in the vitreous proteomic study (Table 2), has been assayed in plasma. Levels of PEDF in plasma among those with PDR have been found at 5.3 ± 5.1 ng/mL and among those without at 7.7 ± 6.1 ng/mL (Matsuyama et al., Mol Vis. 2008 May 28;14:992-6). A sample size of 100 cases and 100 controls yields a power of 83% with p ≤0.05). In aqueous Yoshida et al report a mean PEDF level of 1.8 ±0.2 ng/mL among those with DR and 6.4 ±0.8 ng/mL among those without (Br J Ophthalmol. 2007 Sep;91(9): 1133-4).
- The prevalence of DR in the Medalists evaluated is shown in
FIG.4 . Candidate factors that protect against DR were identified by comparing the levels or expression of factors in individuals with DR and those without DR. Factors with a statistically significant difference in expression between the individuals with DR and those without DR were selected. A total of 700 candidate factors were selected. Further statistical analysis was then applied to select protective factors from the candidate factors. After applying kruskal-wallis statistical analysis, a total of 22 protective factors (the first 22 factors in the Table, i.e., those above the black line) and 3 risk factors (the last three lines in the Table, i.e., those under the black line) were identified, as shown in Table 4 andFIG. 7. FIG.7 lists only the protective factors. The criteria of the selection for the protective factors was p value <0.05, and expression level increased > = 1.5 fold in individuals without DR (i.e. no to mild NPDR). - The analysis was performed essentially as follows. The protein analysis was done using a label-free quantitative analysis of 1D PAGE-LC/MS/MS-based proteomics. Soluble proteins from vitreous tissues of 50-Year Medalists were loaded onto 10% acrylamide protein gels for separations in 1-D gel electrophoresis. We loaded 50uL (micro liter) of vitreous fluid with sample buffer in each sample lane on the gel. Then the gel was stained with Coomassie Blue. Each lane of gel was then cut into 40 slices. The 40 slices were digested in separate tubes by trypsin. These digested protein gel slices were then loaded into an LC machine for the later MS/MS analysis.
- The number of peptide hits was obtained from the "MS manager," software previously developed by Benbo Gao (Gao B et al. Mol Cell Proteomics 2008;7:2399-2409). MS manager is designed based on the PHP-MySQL-Apache platform. It compiles the search results from SEQUEST and X! Tandem of MS/MS data, and then parses these results into the MySQL database. After applying the algorithm for filtering proteins and combining the IPI identifier, a final report of identified proteins is generated in a table with peptide hit numbers. The results are shown in Table 4 below.
- The first column in Table 4 shows the names of DR protective factors. The second column shows the International Protein Index numbers (IPI numbers) of the protective factor proteins. These accession numbers were retrieved from mass spectrometry analysis result, mapped to EMBI-EBI IPI database. Columns 3-7 and columns 9-15 show the peptide hits of each factor (reflecting the expression level) from each vitreous sample. Columns 3-7 are hits in samples from subjects having no-mild NPDR, and columns 9-15 are hits from subjects having PDR. The first line of the Table refers to the grade of the DR from which each of the samples were obtained (e.g., "2," "3," and "0," refer to
NPDR grades Column 8 is the average number of hits in no-mild NPDR samples, compiled from columns 3-7 for each factor.Column 16 is the average number of hits in PDR samples, complied from columns 9-15. Column 17 shows the fold difference between the average number of hits in the no-mild NPDR samples (column 8) to the average number of hits in the PDR samples (column 16) for each factor. The fold increase column shows that the factors are expressed at higher levels intype 1 diabetic individuals without DR compared to those with DR. - Complications observed in Medalists are shown in
FIG. 5 and a summary of clinical characteristics in Medalists is shown inFIG. 6 . Candidate factors that protect against DN were identified by comparing the levels or expression of factors in individuals with DN and those without DN. Factors with a statistically significant difference in expression between the individuals with DN and those without DN were selected. A total of 1709 candidate factors were selected. Further statistical analysis was then applied to select protective factors from the candidate factors. After applying kruskal-wallis statistical analysis, a total of 15 protective factors (first 15 entries in Table 5, i.e., those above the line in the middle of the Table) and 17 risk factors (bottom 17 entries in Table 5, i.e., those below the line in the middle of the table) were identified, as shown in Table 5 andFIG. 8. FIG. 8 only lists the protective factors. The criteria of the selection for protective factors was p value <0.05, and expression level increased > = 1.5 fold in individuals without DN. The criteria of the selection for risk factors was p value <0.05, and expression level increased <= 0.67 fold in individuals without DN (i.e., decreased >=1.5 fold in individuals with DN). - The analysis was performed essentially as follows. The protein analysis was done using a label-free quantitative analysis of 1D PAGE-LC/MS/MS-based proteomics. Soluble proteins from vitreous tissues of 50-Year Medalists were loaded onto 10% acrylamide protein gels for separations in 1-D gel electrophoresis. We loaded 200ug (micro gram) of protein-prep (isolated by sieving, buffering, centrifuging, etc. several steps.) with sample buffer in each sample lane on the gel. Then the gel was stained with Coomassie Blue. Each lane of gel was then cut into 40 slices. The 40 slices were digested in separate tubes by trypsin. These digested protein gel slices were then loaded into an LC machine for the later MS/MS analysis.
- The number of peptide hits was obtained from the "MS manager," software previously developed by Benbo Gao (Gao B et al. Mol Cell Proteomics 2008;7:2399-2409). MS manager is designed based on the PHP-MySQL-Apache platform. It compiles the search results from SEQUEST and X! Tandem of MS/MS data, and then parses these results into the MySQL database. After applying the algorithm for filtering proteins and combining the IPI identifier, a final report of identified proteins is generated in a table with peptide hit numbers. The results are shown in Table 5 below.
Table 5: Protective and Risk Factors for DN Accession Protein Name G7 G4 G3 Clean Mean G11 G8 G6 G2 G1 G12 G9 G10 G5 Dz mean Fold P_KW IP|00789618 HDDC3 Isoform 1 of HD domain-containingprotein 33 3 0 2.00 0 0 0 0 0 0 0 0 0 0.00 #DIV/0! 0.01 IP|00178926 IGJ immunoglobulin J chain 0 45 18 21.00 0 0 0 0 0 0 0 8 0 0.89 23.63 0.04 IP|00816799 Rheumatoid factor D5 light chain (Fragment) 4 0 3.67 0 3 0 0 0 0 0 0 0 0.33 11.00 0.04 IP|00410215 BPNT1 Isoform 2 of 3(2),5-bisphosphate nucleotidase 1 4 4 0 2.67 0 0 0 3 0 0 0 0 0 0.33 8.00 0.04 IP|00009305 GNPDA1 Glucosamine-6-phosphate isomerase 4 3 4 3.67 0 0 5 0 0 0 0 0 0 0.56 6.60 0.02 IP|00873466 HPRT1 Uncharacterized protein HPRT1 6 4 5 5.00 3 3 5 0 0 0 0 0 0 1.22 4.09 0.02 IP|00893316 GSTT1 Glutathione S-transferase theta 1 30 23 20 24.33 4 10 25 11 4 0 0 0 9 7.00 3.48 0.03 IP|00004101 BHMT Betaine-homocysteine 5-rnethyltransferase 1 182 74 118 124.67 17 105 60 78 29 16 10 0 33 38.67 3.22 0.03 IP|00848298 APOA1BP Isoform 2 of Apolipoprotein A-I-binding protein precursor 8 8 10 8.67 0 3 4 4 5 0 4 3 6 3.22 2.69 0.01 IP|00022488 HPX Hemopexin precursor 20 24 25 23.00 10 8 19 12 10 0 0 5 21 9.44 2.44 0.02 IP|00218407 ALDOB Fructose-bisphosphate aldolase B 690 450 521 553.67 76 486 381 428 176 84 34 36 414 235.00 2.36 0.02 IP|00305360 AGMATAgmatinase, mitochondrial precursor 54 38 57 49.67 4 54 23 35 20 8 19 18 9 21.11 2.35 0.03 IP|00792191 GATM Glycine amidinotransferase (L-arginine:glycine amidinotransferase) variant 213 177 222 204.00 32 207 111 149 64 60 74 108 57 95.78 2.13 0.02 IP|00219446 PEBP1 Phosphatidylethanolamine-binding protein 1 235 235 171 213.67 30 227 129 203 97 32 24 25 145 101.33 2.11 0.03 100025366 CS Citrate synthase, mitochondrial precursor 30 17 21 22.67 7 11 10 19 8 8 12 10 14 11.00 2.06 0.02 IP|00554811 TTLL3;ARPC4 Actin-related protein 2/3 complex subunit 4 4 5 4.33 16 8 6 7 6 12 17 5 4 9.00 0.48 0.04 IP|00215948 CTNNA1 Isoform 1 of Catenin alpha-1 5 13 3 7.00 26 6 17 14 16 20 18 22 11 16.67 0.42 0.03 IP|00010796 P4HB Protein disulfide-isomerase precursor 26 8 23 19.00 65 29 39 26 48 74 52 57 22 45.78 0.42 0.04 IP|00646415 RAB14 20 kDa protein 4 6 5.67 7 11 23 11 7 8 36 23 19 16.11 0.35 0.02 IP|00025447 EEF1A1 Elongation factor 1-alpha 9 2 5.33 9 14 15 15 21 4 35 15 20 16.44 0.32 0.04 IP|00413947 AP1B1 Isoforrn B of AP-1 complex subunit beta-1 7 0 4.33 10 12 13 6 9 22 26 11 17 14.00 0.31 0.03 IP|00009904 PDIA4 Protein disulfide-isomerase A4 precursor 8 6 4 6.00 23 16 24 15 16 17 19 27 20 19.67 0.31 0.01 IP|00020599 CALR Calreticulin precursor 7 11 25 14.33 46 18 30 51 23 43 133 89 30 51.44 0.28 0.03 IP|00401448 ACSL1 Isoform 2 of Long-chain-fatty-acid-CoA ligase 1 3 2 3 2.67 22 11 4 6 0 11 28 4 4 10.00 0.27 0.05 IP|00792916 PRKCSH protein kinase C substrate 80K-H isoform 2 0 4 2.33 14 4 9 5 4 15 20 14 6 10.11 0.23 0.02 IP|00025252 PDIA3 Protein disulfide-isomerase A3 precursor 5 12 8 8.33 72 12 29 26 30 30 85 58 27 41.00 0.20 0.02 IP|00008274 CAP1 Adenylyl cyclase-associated protein 1 5 0 0 1.67 13 4 10 4 7 16 15 6 5 8.89 0.19 0.04 IP|00783726 KTN1 kinectin 1 isoform b 0 3 0 1.00 5 7 8 5 8 5 2 6 6 5.78 0.17 0.02 IP|00025239 NDUFS2 NADH dehydrogenase [ubiquinone] iron-sulfur protein 2, mitochondrial precursor 0 3 0 1.00 20 4 5 3 2 12 3 10 4 7.00 0.14 0.03 IP|00217943 RAB6A Isoform 2 of Ras-related protein Rab-6A 2 0 0 0.67 0 7 8 2 2 8 14 8 3 5.78 0.12 0.05 IP|00016621 AP2A2 Adaptor-related protein complex 2, alpha 2 subunit variant (Fragment) 0 0 0 0.00 13 2 4 2 3 13 21 12 3 8.11 0.00 0.01 IP|00025874 RPN1 Dolichyl-diphosphooligosaccharide-protein glycosyltransferase 67 kDa subunit pre 0 0 0 0.00 33 6 6 2 0 36 32 23 0 15.33 0.00 0.04 - The first column in table 5 shows the International Protein Index numbers (IPI numbers) of the protective factor proteins. These accession numbers were retrieved from mass spectrometry analysis result, mapped to EMBI-EBI IPI database. The second column shows names of DN protective factors. Columns 3-5 and columns 7-15 show the peptide hits of each factor (reflecting the expression level) from each kidney sample. Columns 3-5 are hits in samples from subjects with no DN, and columns 7-15 are hits in samples from subjects with DN. The first line (listing, e.g., "G7") refers to the names of each sample. Column 6 ("Clean Mea") shows the average number of hits in the non-DN samples, compiled from columns 3-5 for each factor.
Column 16 is the average number of hits in the DN samples, compiled from columns 9-15. Column 17 shows the fold difference between the average number of hits in the no-DN samples (column 6) to the average number of hits in the DN samples (column 16) for each factor. The fold column shows that the protective factors (factors 1-15, i.e., those above the line) are expressed at higher levels intype 1 diabetic individuals without DN compared to those with DR. It also shows that the risk factors (factors 16-32, i.e., those below the line) are expressed at lower levels intype 1 diabetic individuals without DN relative to those with DN. - Vitreous from 6 eyes (4 Medalists) from the no to Mild-NPDR and 8 vitreous (5 Medalists) from the PDR groups. "No to mild NPDR" is characterized as Early Treatment Diabetic Retinopathy Study (ETDRS) severity levels 10-35, characterized by absent or less than severe hemorrhages/microaneurysms throughout the retina (Grading diabetic retinopathy from stereoscopic color fundus photographs--an extension of the modified Airlie House classification.
ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1991May;98(5 Suppl):786-806. PubMed PMID: 2062513; and Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1991 May;98(5 Suppl):823-33. PubMed PMID: 2062515). 10 microliters of sonicated and centrifuged vitreous from each sample were loaded onto a 4-20% gel (Biorad) and transferred to a PVDF membrane (Immobilon-P). CystatinC, RBP3 and PTGDS (Abcam, 1:2000), Endophilin and Tenascin R (Santa Cruz 1:1000) were used for immunodetection. More specifically, rabbit anti-RBP3 (Abcam 101456) was used and Santa Cruz HRP anti-Rabbit was used as the secondary antibody for detection. The band density was analyzed using Image J, and p values represent student t test. - Western Blot confirmed that RBP3 protein levels are significantly higher in vitreous of Medalists without PDR than in vitreous from Medalists with PDR (pval=0.01;
Figure 11 ). Cystatin C protein levels showed a similar trend (pval=0.06). Although the difference in PTGDS levels between both groups was not statistically significant, we decided to pursue this protein as well, since it belongs to the lipocalin superfamily (as does RBP3), and can bind to the same substrates. - CST3 is universally expressed. We confirmed that CST3 is detected in mouse retina protein extracts by Western blot (data not shown). RBP3 is secreted by the retinal photoreceptor cells (RPE), and thus, it could play a role in retinal endothelial cells and pericytes even when those cells do not express RBP3.
- RBP3 was also quantified in the vitreous of Medalists with no-mild NPDR, active PDR or quiescent PDR by proteomics analysis. No to mild NPDR is as described above. "Quiescent PDR" corresponds to ETDRS severity level > 60, characterized by the presence of neovascularization, fibrous proliferation, or panretinal laser photocoagulation scars.
- The results, which are shown in
Figure 12 , indicate that the level of RBP3 is high in Medalists with no DR, low in Medalists with active PDR and present at an intermediary level in Medalists with quiescent PDR. This data shows that the Medalist patients without PDR have retained high levels of RBP3 despite a long duration of type1 diabetes. - The level of RBP3 was also determined in the vitreous of Medalists with no to mild NPDR and compared to that in Medalists with PDR using proteomics analysis. The results, which are shown in
Figure 13 , indicate that the level of RBP3 is higher in Medalists with no to mild NPDR relative to that in Medalists with PDR. - The level of RBP3 was also determined in the retina of Medalists with mild NPDR and Medalists with PDR. The assay was conducted as follows: 10 ug of protein were loaded onto a 4-20% gel (Biorad) and transferred to a PVDF membrane (Immobilon-P) and immunoblotted as described above.
- The results, which are shown in
Figure 14 , indicate that the level of RBP3 follows the same trend as the vitreous, i.e. higher RBP3 in the retina of Medalists with mild NPDR relative to that in Medalists with PDR. - This Example describes that plasma from healthy human subjects contain detectable levels of RBP3. This was surprising, as RBP3 was so far believed to be present only in the eye.
- Human plasma was obtained from control subjects from the Medalist study at the Joslin Diabetes Center. A blood sample was extracted by venipuncture using standard CLIA protocol after patient consent was obtained using a 10mL EDTA tube by a trained phlebotomist. This was then centrifuged at 4 degrees centigrade for 10 mins at 4000 rpm. After this process the supernatant (plasma) was aliquotted off into 100 mL samples and stored at -80 centigrade. The human plasma was serum albumin and IgG depleted using Pierce kit (89875) following the manufacturers instructions. Equal volumes (20ul) were loaded on a gel and immunoblotted as described above.
- The results, which are shown in
Figure 15 , indicate that RBP3 is present in human plasma. - This Example describes that human RBP3 protects endothelial cells from being activated by high glucose exposure, as shown in an endothelial migration assay.
- Human RBP3 was prepared as follows: hRBP3 ORF containing plasmid was purchased from Origene (RC08063), transfected into HEK 293 cells using Fugene HD (Promega), the cells lysed and RBP3 was bound to M2 resin (Sigma, Aldrich) and eluted using 1XFlag peptide (Sigma) following the manufacturer's instructions. The purified peptide was confirmed by immunoblotting against the DDK tag, and a 137 kDa band was confirmed.
- The migration assays were performed as follows: bovine retinal endothelial cells (BREC) were isolated as previously described (King et al, J Clin Invest. 1983;71(4):974-979). 3 x 104 per well were plated in a 24 well plate. The following day, a scratch was made, the cells rinsed off with saline to remove floating cells, and incubated with different conditions (low glucose= 5.6 mM, high glucose=25.6 mM D-glucose, Vehicle =TBS buffer, RBP3= 1:100 dilution). The width of this gap was measured at 0 and 4 hours in the corresponding conditions, two pictures of each gap were taken at each time point and the average was used. Four wells were plated for each condition. Statistics were done with excel (student ttest).
- The results, which are shown in
Figure 16 , indicate that RBP3 prevents the endothelial cells from migrating in response to the high glucose concentration, thereby indicating that RBP3 protects endothelial cells from the toxic effects of a high glucose environment. - It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.
Claims (6)
- A therapeutic agent for use in treating diabetic retinopathy (DR) in a subject, characterised in that the therapeutic agent comprises interphotoreceptor retinoid-binding protein precursor (RBP3).
- The therapeutic agent for use according to claim 1, characterised in that the therapeutic agent is administered systemically.
- The therapeutic agent for use according to claim 1, characterised in that the therapeutic agent is administered locally to the eye.
- The therapeutic agent for use according to claim 3, characterised in that the therapeutic agent is injected into the vitreous of the eye.
- The therapeutic agent for use according to claim 1, characterised in that the agent can be used to further determine the effectiveness of the treatment.
- The therapeutic agent for use according to claim 1, characterised in that the RBP3 is of recombinant origin.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42068610P | 2010-12-07 | 2010-12-07 | |
PCT/US2011/046672 WO2012019060A1 (en) | 2010-08-05 | 2011-08-04 | Predicting and treating diabetic complications |
PCT/US2011/063514 WO2012078618A2 (en) | 2010-12-07 | 2011-12-06 | Predicting and treating diabetic complications |
Publications (3)
Publication Number | Publication Date |
---|---|
EP2649206A2 EP2649206A2 (en) | 2013-10-16 |
EP2649206A4 EP2649206A4 (en) | 2015-07-08 |
EP2649206B1 true EP2649206B1 (en) | 2017-04-26 |
Family
ID=46207682
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP11847055.8A Active EP2649206B1 (en) | 2010-12-07 | 2011-12-06 | Predicting and treating diabetic complications |
Country Status (3)
Country | Link |
---|---|
US (1) | US9283262B2 (en) |
EP (1) | EP2649206B1 (en) |
WO (1) | WO2012078618A2 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014018851A1 (en) * | 2012-07-26 | 2014-01-30 | Joslin Diabetes Center, Inc. | Predicting and treating diabetic complications |
EP3294332A4 (en) * | 2015-05-14 | 2018-12-26 | Joslin Diabetes Center, Inc. | Retinol-binding protein 3 (rbp3) as a protective factor in non-diabetic retinal degeneration |
HUE055326T2 (en) * | 2015-12-10 | 2021-11-29 | Univ California | Compositions for use in treating or ameliorating neuroinflammation, neurodegeneration, neuropathic pain, and migraine |
CN109991342B (en) * | 2019-03-08 | 2022-02-15 | 首都医科大学附属北京同仁医院 | Biomarker for diagnosing or preventing diabetic retinopathy, detection reagent and application |
EP4157312A1 (en) * | 2020-05-27 | 2023-04-05 | Baylor College of Medicine | Compositions and methods for treating neovascularization and ischemic retinopathies by targeting angiogenesis and cholesterol transport |
CN113917152B (en) * | 2021-09-22 | 2024-05-31 | 北京松果天目健康管理有限公司 | Application of urine protein marker in preparation of kit for detecting diabetic nephropathy |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7247702B2 (en) * | 2002-02-28 | 2007-07-24 | The Penn State Research Foundation | Periocular drug delivery for diabetic retinopathy |
AU2003227308A1 (en) * | 2002-03-26 | 2003-10-08 | Yeda Research And Development Co. Ltd | Use of an organ-specific self-pathogen for treatment of a non-autoimmune disease of said organ |
US20100150920A1 (en) * | 2008-12-04 | 2010-06-17 | Bert Glaser | System and Method for Identifying Biomarkers in Ocular Fluid That Are Indicative of Ocular Disease |
-
2011
- 2011-12-06 EP EP11847055.8A patent/EP2649206B1/en active Active
- 2011-12-06 US US13/992,149 patent/US9283262B2/en active Active
- 2011-12-06 WO PCT/US2011/063514 patent/WO2012078618A2/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2012078618A2 (en) | 2012-06-14 |
EP2649206A2 (en) | 2013-10-16 |
US20140187498A1 (en) | 2014-07-03 |
WO2012078618A3 (en) | 2013-09-12 |
EP2649206A4 (en) | 2015-07-08 |
US9283262B2 (en) | 2016-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2649206B1 (en) | Predicting and treating diabetic complications | |
US9921221B2 (en) | Predicting and treating diabetic complications | |
Nitta et al. | Fibroblast growth factor 23/klotho axis in chronic kidney disease | |
Pugliese et al. | Accelerated diabetic glomerulopathy in galectin‐3/AGE receptor 3 knockout mice | |
Vylet'Al et al. | Alterations of uromodulin biology: a common denominator of the genetically heterogeneous FJHN/MCKD syndrome | |
Schmid et al. | U1 snRNA‐mediated gene therapeutic correction of splice defects caused by an exceptionally mild BBS mutation | |
JP2012508247A (en) | Role of soluble uPAR in the pathogenesis of proteinuria | |
Zhang et al. | DNase I improves corneal epithelial and nerve regeneration in diabetic mice | |
US20200397870A1 (en) | Recombinant alkaline phosphatase for use in treating sepsis-associated acute kidney injury | |
WO2012019060A1 (en) | Predicting and treating diabetic complications | |
EP3259599B1 (en) | Biomarkers for diagnosis and prognosis of corneal ectatic disorders | |
Wang et al. | YY1 alleviates lupus nephritis-induced renal injury by reducing the Th17/Treg cell ratio via the IFN-γ/Fra2 axis | |
Shen et al. | Role of uromodulin and complement activation in the progression of kidney disease | |
Hacıhamdioğlu et al. | Urinary netrin-1: a new biomarker for the early diagnosis of renal damage in obese children | |
EP2930247A1 (en) | Biomarker of prognosis and acute-on chronic liver failure in cirrhosis | |
Cai et al. | Adenoviral transduction of Dickkopf-1 alleviates silica-induced silicosis development in lungs of mice | |
Wang et al. | Upregulation of C/EBP homologous protein induced by ER stress mediates epithelial to Myofibroblast transformation in ADTKD-UMOD | |
US20210000855A1 (en) | Retinol-binding protein 3 (rbp3) as a protective factor in non-diabetic retinal degeneration | |
EP1882937B1 (en) | Method for diagnosis of severity and prediction of recurrence in eosinophilic inflammatory disease | |
Bonomo et al. | Association analysis of the reticulon 1 gene in end-stage kidney disease | |
Cunningham et al. | Adenoviral expression of NHERF-1 in NHERF-1 null mouse renal proximal tubule cells restores Npt2a regulation by low phosphate media and parathyroid hormone | |
Ibarretxe et al. | Impact of epidermal fatty acid binding protein on 2D-NMR–assessed atherogenic dyslipidemia and related disorders | |
US20100143950A1 (en) | Binding of complement factor h to c-reactive protein | |
Sahajpal et al. | Deranged metabolic profile and identification of biomarkers in the vitreous humour of patients with proliferative diabetic retinopathy | |
Atef et al. | Biochemical significance of soluble endoglin as a possible marker predicting cardiovascular diseases in obese and obese type 2 diabetic patients |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20130611 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C12Q 1/68 20060101AFI20150527BHEP Ipc: G01N 33/53 20060101ALI20150527BHEP |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20150608 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Ref document number: 602011037431 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: C12Q0001680000 Ipc: A61K0038170000 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 38/17 20060101AFI20161117BHEP Ipc: C12Q 1/68 20060101ALI20161117BHEP Ipc: G01N 33/53 20060101ALI20161117BHEP |
|
INTG | Intention to grant announced |
Effective date: 20161128 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 887296 Country of ref document: AT Kind code of ref document: T Effective date: 20170515 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602011037431 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20170426 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 887296 Country of ref document: AT Kind code of ref document: T Effective date: 20170426 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170426 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170727 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170426 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170726 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170426 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170426 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170426 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170426 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170426 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170826 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170426 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170426 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170426 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170726 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602011037431 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170426 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170426 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170426 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170426 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170426 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170426 Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170426 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20180129 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170426 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602011037431 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171206 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171206 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20180831 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20171231 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180703 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171206 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180102 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171231 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171231 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171231 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20111206 Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170426 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170426 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170426 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170426 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170426 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170426 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230614 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20231227 Year of fee payment: 13 |